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ABSTRACf 
Nutrition and Bone Density in Children with Cystic Fibrosis 
by 
Joanna K. Davidson, Master of Science 
Utah State University, 2004 
Major Professor: Dr. Nedra C. Christensen 
Department: Nutrition and Food Sciences 
Ill 
The purpose of these studies was to further research on bone density in children 
with cystic fibrosis, particularly as it pertains to nutritional parameters and care. The first 
paper presented a comparison of a group of 50 children with cystic fibrosis to a group of 
32 control children. There were no significant differences between the groups in any of 
the pertinent bone density measurements. Serum 25(0H) vitamin D was positively 
correlated with spine density z score in the cystic fibrosis group. 
The second paper, incorporating all of the information obtained from the first 
paper, describes an intervention study with the implementation of a fortified milk to 
determine the effects of additional calcium and vitamin Don bone density in the cystic 
fibrosis group. A follow-up bone scan was done. The fortified milk did not significantly 
improve bone density, but the fortified milk group did have significantly higher lung 
function scores on follow-up. 
(122 pages) 
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CHAPTER 1 
GENERAL BACKGROUND AND INTRODUCfiON 
Definition of Cystic Fibrosis 
Cystic fibrosis (CF) is a genetic disease that affects approximately 30,000 
children and adults in the United States.' In CF, the transport of sodium and chloride 
within cells lining organs (such as the lungs and pancreas) to their outer surfaces is 
faulty.' This causes the body to produce an abnormally thick, sticky mucus.' Nearly all 
exocrine glands are affected to varying degrees,2 but it is the lungs and pancreas that are 
most notably affected in most patients. Fifty percent of all patients presented with 
pulmonary symptoms including chronic cough and wheezing due to recurrent or chronic 
pulmonary infections. 2 Pancreatic insufficiency is present early in life but may be 
progressive. 2 Seven to 10% of CF patients have meconium ileus at birth.2 There are 
clinical manifestations of pancreatic insufficiency in 85 to 90% of patients. 2 
The most common symptoms of CF include very salty-tasting skin; persistent 
coughing, wheezing, or pneumonia; excessive appetite but poor weight gain; and bulky 
stools. 1 The standard diagnostic test for CF is the "sweat test" which measures the 
amount of salt in sweat. 1 Sweat chloride concentrations less than 40 mmoi/L are normal; 
concentrations greater than 60 mmoi/L are consistent with the diagnosis of CF. 1 
Diagnosis can be confirmed by DNA analysis in a patient with clinical correlates by 
finding two known disease-causing mutations.3 
CF is an autosomal recessive disease, and thus, to have CF an individual must 
inherit a defective copy of the CF gene from both parents. 1 More than 10 million 
individuals in the U.S. (one in 31) is a symptom-less carrier of the defective gene.1 
2 
Ninety percent of patients are diagnosed in infancy or early childhood.2 From 1985 
through 2001, predicted survival increased from about 25 years to about 33 years.4 This 
is evidence of the great progress made in CF research and consequent treatments in recent 
years. Current common treatments include chest physical therapy (vigorous percussion 
on the back and chest to dislodge the thick mucus from the lungs), antibiotics to treat 
lung infections (administered intravenously, via pills, and/or medicated vapors which are 
inhaled to open up clogged airways), an enriched diet, replacement vitamins, and 
pancreatic enzymes. 1 
The recent increase in life span of patients over a 16-year period has evidenced a 
new set of long-term complications. These include diabetes, liver disease, malnutrition, 
suboptimal growth, infertility, and osteopenia.5 Osteopenia in CF patients can lead to 
osteoporotic fractures prematurely, which decreases quality of life and increases medical 
costs. Now that length of life is increasing, it is equally important that quality of life 
increase with it. 
Evidence of Osteopenia in Cystic Fibrosis 
Bone mineral density (BMD) deficiencies in patients with CF were first published 
in 1979 by Mischler et al. 6 They used photon absorptiometry to measure the radius and 
ulna in 27 patients with CF (range of ages not reported) and compared them with 968 
age-matched controls. They found significant demineralization in 44%of the CF patients. 
3 
Aris et al. 7 increased awareness of this problem with their reports of rib and vertebral 
fractures and high fracture rates in a study of 70 adult patients referred for lung 
transplantation. They found that vertebral compression and rib fractures were 100- and 
10-fold (respectively) more common than expected and that the extent of kyphosis, and 
osteoporosis were higher than those of age-matched normal controls. A growing number 
of researchers have turned their attention to this problem in recent years. 
Donovan et al.,8 Grey et al.,9 Bachrach et al.,5 and Laursen eta!. 10 looked at adult 
CF patients and found significantly decreased BMD. Once it became apparent that 
osteopenia was a significant problem in the adult CF population, the question of when 
bone mineral deficiencies began became the subject of several research studies. Many 
researchers decided to include children and/or adolescents in their study populations. 
Gibbens et al., 11 Haworth et al., 12 two separate studies by Henderson and Madsen, 1314 and 
two separate studies by Bhudkhikanok et al. 15' 16 still found decreased bone density in 
these combined age group study populations. 
Other researchers 17' 18' 19 have found little or no evidence of bone mineral 
deficiencies in CF groups. It should be noted that these studies were all done on young 
CF populations with relatively mild disease. It is generally accepted that significant 
BMD deficiencies are problematic in adult CF populations, but when and why they begin 
is still not clearly understood. 
Osteoporosis is usually the result of bone loss, which commonly occurs as adults 
age, but this is not always the case. Osteoporosis can also occur without accelerated bone 
loss when peak bone mass is not attained during childhood and adolescence. Factors 
affecting bone metabolism in children with CF may be especially complicated because 
4 
this population may risk both not reaching peak bone mass and early bone loss. 
Therefore, the periods of childhood and adolescence may be an especially important time 
to study bone density in CF. Much of the research done on bone density in CF is carried 
out with adult groups or combined youth and adult groups, in which 
children/prepubescent youth are not considered separately from adult/pubescent youth. 
Sex steroids secreted during puberty substantially increase BMD and because the age at 
onset of puberty can greatly differ in individuals, it is difficult to interpret and compare 
BMD/bone mineral content (BMC) results within a group of combined 
pubescent/prepubescent youths. 
Only one published study was found that reported on a significantly sized group 
of prepubescent CF patients (and this study was published after our study was under 
way). Haslam et al. 20 studied 22 prepubertal children with CF and found only a non-
significant mild reduction in mean total body BMC. More research on prepubertal 
children with CF was needed. This research could be especially important because the 
prepubertal period may be an ideal time for preventive measures to be implemented. 
Possible Causes of Osteopenia in Cystic Fibrosis 
There are several known risk factors associated with low bone density. These 
include female gender, estrogen deficiency, increasing age, family history of 
osteoporosis, caucasian race, low body weight/body mass index (BMI), physical activity 
and smoking. Alcohol and caffeine intake and age at menarche and menopause may also 
be associated with decreased bone density. Although some of these risk factors may be 
applicable in the case of CF patients, osteopenia in CF is definitely different than 
osteopenia in the general population. 
5 
There are several pathogenic factors of CF that could contribute to risk for low 
bone density. Many of them are related to poor nutritional status. Eighty-five to 90% of 
children with CF have exocrine pancreatic insufficiency which occurs when 98% of 
pancreatic exocrine function is lost. 21 This leads to malabsorption of dietary nutrients 
(including calcium, magnesium, and vitamins D and K). 
Although pancreatic enzyme replacement therapy is used to treat malabsorption, 
even optimal use of enzymes cannot fully compensate for pathogenic deficiencies. 
Benabdeslam et al. 22 demonstrated this when they conducted biochemical assessment on 
65 CF patients who were being treated with pancreatic enzyme replacement therapy and 
found that despite treatment, malnutrition was not completely corrected. Ninety-three 
percent of CF patients take pancreatic enzyme supplements.4 Published nutritional 
recommendations for both energy intake and specific nutrients for CF patients are higher 
than those for healthy populations, but are nearly impossible to precisely determine for 
individuals in various stages of growth and disease progression. 
Malabsorption can lead to undernutrition resulting in suboptimal growth. It could 
also theoretically decrease peak bone mass (due to both suboptimal growth and 
malabsorption of bone metabolism-related nutrients, specifically calcium and vitamin D). 
Fat malabsorption, specifically, can additionally contribute to risk because not only is 
absorption of fat-soluble vitamins (like vitamin D) reduced, but it also produces excess 
fat in the stool to bind with dietary calcium. Eighteen percent of children with CF fall 
below the 5th percentile for weight and 16% fall below the 5th percentile for height.4 BMI 
6 
has been well documented as a predictor of BMD. No published studies were found on 
the effect of calcium fortification on bone density in CF. 
Chronic diseases can alter body composition and delay sexual maturation. 
Delayed puberty (in adolescents) and hypogonadism (in adults) may affect bone 
metabolism. Delay in pubertal development is usually related to poor nutritional status 
and growth failure, rather than to a rare primary endocrine disorder.23 Delayed puberty 
may interfere with peak bone mass accretion, as shown by Henderson and Madsen 13 in 
their study of 62 CF patients under 18 years of age. They found that although absolute 
BMD increased with age, when converted to a z score, it actually declined relative to 
normal values at a rate of approximately I standard deviation (SD) every 6 to 8 years. To 
further the problem, adults with hypogonadism may have accelerated bone loss. Better 
research in pre-prepubescent CF populations may help determine the importance of these 
possible risk factors in the etiology of low bone density. 
It is generally accepted that patients who chronically use corticosteroid 
medications for lung disease are at increased risk for poor bone health. In addition to 
possibly decreasing calcium absorption and suppressing linear growth/ 4 corticosteroid 
therapy may suppress osteoblastogenesis and promote apoptosis of osteoblasts and 
osteocytes. 25 Steroid use alone is not responsible for the decreased bone density seen in 
CF, and in fact, low bone density is seen in patients who do not use corticosteroids. 
Research results like those from Bachrach et al. 5 further confuse the issue. They found in 
their study that glucocorticoid therapy was not predictive of BMD. Therefore, the extent 
of its effect on bone density in CF is not fully understood. 
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Weight-bearing physical activity also affects bone density. The acquisition of 
maximal bone density is dependent upon getting adequate weight-bearing activity. Bass 
et al./6 Khan et al.,27 and Jones and Dwyers all concluded from their research results that 
the prepubertal period may be vitally important in terms of the effects of physical activity 
on bone mass. Historically, children with CF were believed to be less active than 
healthy children due to decreased lung function and, consequently, decreased energy 
levels. However, the activity level differences between CF and non-CF children are now 
minimal.25 Conway et al.,29 Bhudhikanok et al., 16 and Haworth et al. 12 found a significant 
positive association between BMD and physical activity. However, others, like Grey et 
al.,9 have found no association. 
Finally, disease severity may be an important factor for predicting BMD status in 
CF. Although several different factors can be taken into account when determining 
disease severity, chronic pulmonary infection and chronic respiratory acidosis 
specifically can negatively affect bone metabolism. In more severe cases of CF, the 
ongoing catabolic status and circulating inflammatory mediators (fNF-a, IL-l and IL-6) 
are characteristic and can lead to an imbalance between bone formation and 
resorption.30'3 1 Henderson and Madsen 13 and Haworth et al. 12 found a relationship 
between BMD z scores and percent predicted forced expiratory volume in 1 second 
(FEV 1%). Bachrach et al. 5 and Haslem et al. 20 did not find a relationship between BMD 
and disease severity. 
This study is unique in that only pre-pubescent children with CF (and matched 
healthy controls) were recruited for the study in significant numbers. The purposes of 
this study are to evaluate the differences in bone mineralization between children with CF 
and healthy control children. The results of this study will hopefully help health 
professionals to identify children in the CF population at risk for osteopenia. 
Hypotheses 
The hypotheses of this study are: ( 1) children with CF are smaller than healthy 
children without CF; (2) children with CF have less dense bones than healthy children 
without CF; (3) calcium intake is correlated with bone density in both children with CF 
and healthy children without CF. 
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CHAPTER2 
BONE DENSITY IN CHILDREN WITH CYSTIC FIBROSIS 
Abstract 
Aim--To compare bone density in children with cystic fibrosis (CF) and healthy children 
without CF, and to determine clinical correlates of bone density in both groups. 
Methods-In 51 children with mild CF and 32 controls (ages 3-13), bone mineral density 
(BMD) of the lumbar spine (L2-lA) and proximal and distal radius and ulna were 
measured using dual energy x-ray absoptiometry (DEXA). The relation between BMD 
and anthropometrical measurements, dietary intake, biochemical indices, lung function 
and activity level were studied. 
Results-Although the CF group was significantly lower in weight-for-age and height-
for-age than the controls, they did not significantly differ from the controls in any 
measures of bone density. The CF group had significantly higher dietary intake of 
calories, protein, calcium and vitamin D than the control group. In the control group, 
there was a significant correlation between calcium intake and spine density z score. In 
the CF group, serum 25 hydroxyvitamin D (25(0H)D) levels were positively correlated 
with spine density z scores. 
Conclusions-There were no bone deficits in this pre-pubescent CF population. Even 
though no dietary correlates for BMD were observed in the CF children, sup-optimal 
intakes or malabsorption, as well as worsening disease severity with age, may contribute 
to deficits over time. 
12 
Introduction 
Great advances in CF care have occurred in recent years. From 1985 through 
2001, predicted survival for CF patients increased from about 25 years of age to about 33 
years of age. 1 This increase in life span has led to the development of a new set of long-
term complications. These include diabetes, liver disease, malnutrition, suboptimal 
growth, infertility, and osteopenia.2 Osteopenia in CF patients can lead to premature 
osteoporotic fractures, which decrease quality of life and increase medical costs. 
There are several pathogenic factors of CF that could contribute to the risk for low 
bone density. Many of them, like pancreatic insufficiency and suboptimal growth, are 
related to poor nutritional status. Other potential risk factors include delayed puberty in 
adolescents, hypogonadism in adults, chronic use of corticosteroid medications for lung 
disease, inadequate amounts of weight-bearing physical activity, and disease severity. 
Much of the bone density research in CF is conducted with adult groups or 
combined youth and adult groups in which children/prepubescent youth have not been 
considered separately from adult/pubescent youth. This study is unique in that only 
prepubescent children with CF (and matched healthy controls) were recruited for the 
study. This research could be especially important because the prepubertal period may be 
an ideal time for preventive measures to be implemented. 
The purposes of this study are to evaluate the differences in bone mineralization 
between children with CF and healthy control children and to determine which clinical 
variables can be used as predictors of risk for BMD deficits in children with CF. The 
results of this study may be beneficial in the development of clinical screening tools 
and preventive measures for CF patients at risk for osteopenia. 
Methods 
Subjects 
13 
This study was approved by the University of Utah Medical Center's Institutional 
Review Board (JRB). Study participants were recruited from the Outpatient 
Intermountain Cystic Fibrosis Center's clinic at Primary Children's Medical Center 
(PCMC) in Salt Lake City, Utah. This center serves children with CF from Utah, Idaho, 
Wyoming, and Nevada. At the beginning of this study, the CF clinic roster showed 
approximately 150 patients aged 2 to 16 years enrolled at the clinic. A letter describing 
the study, its purpose, and qualifications was sent to all qualified patients, inviting them 
to participate in the study (see Appendices A and C). Additionally, this letter included a 
request for referrals of healthy children without CF to serve as controls in the study (see 
Appendices B and C). Healthy controls were also recruited through advertisement within 
PCMC. 
Fifty-one children with CF and 32 healthy controls ages 3 through 13 enrolled (18 
of these were siblings of CF participants). A signed informed parental consent (see 
Appendices D and E), and when appropriate per patient's age, assent (see Appendix F) 
form was obtained for each participant. All CF participants were to continue all 
treatments prescribed by their physician, including pancreatic enzymes, medications, and 
routine vitamin and mineral supplements per CF clinic protocol? 
Data Collection 
Most recent percent predicted forced expiratory volume in 1 minute (FEV 1%) 
score using Knudson equations4 was obtained for each CF participant. The Knudsen 
equations are categorized as severe ( <40% ), moderate ( 40-69% ), mild (70-89% ), or 
normal (>I= 90%). Because several families had to travel from either another city or 
state to attend CF clinic, volunteer participants began the study on their next scheduled 
routine follow-up appointment. The range of dates for participation in the study were 
1110911998 through 06/101 1999. 
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On the day that volunteers began the study, the study was explained in-depth by 
the graduate student, and any questions the participants or their parents had were 
answered before the consent/assent forms were signed. Preliminary data obtained on each 
subject included history of bone fractures (number, location[s] and cause[s] of) and 
biological parents' self-reported heights (see Appendices G and H). 
The CF participants brought a urine sample (first of that morning in a sterilized 
container, kept on ice) to clinic with them, which was frozen for later measurement of 
calcium, sodium, creatinine, and hydroxyproline. A 5-ml blood sample was obtained and 
frozen for later measurement of calcium, magnesium, phosphorus, 25(0H)D, 1,25 
dihydroxyvitamin D(l,25(0H)2D), parathyroid hormone (PTH), vitamin A, vitamin E, 
and alkaline phosphatase. Urine and serum samples were not obtained from the controls 
due to budget constraints, so normal reference values were used for comparison instead. 
Participants and their parents were instructed on how to keep a 3-day diet record 
(see Appendices I and J) which was to be completed the following 3 days and then 
15 
returned by mail to the graduate student. Diet records were analyzed using Nutritionist 
IV (Nutritionist IV Diet Analysis, 1995 version 4.1, First Data Bank 1111 Bayhill Drive 
San Bruno, CA 94066) to evaluate intake of calories, protein, thiamin, vitamin D, vitamin 
K, calcium, phosphorus, and magnesium. 
Anthropometric measurements were taken by the clinic's registered dietitian. 
Weight was measured on a calibrated platform scale and height with the use of a 
stadiometer. Body mass index (BMI) was calculated using height and weight (kg/m2). 
Mid-arm circumference (MAC) and chest circumference (CC) were measured using a 
standard tape measure. Triceps (TSF) and subscapular skinfold (SS) measurements were 
determined with a Lange caliper, accurate to +/-1mm. De Meer et al. 5 found skinfold 
measurements to be an appropriate tool in monitoring fat-free mass in all children with 
CF. Arm muscle circumference (AMC) was calculated using MAC and TSF [MAC-
(TSFmm):rt]). Arm muscle area (AMA) was calculated using MAC and TSF [[MAC-
:rt(TSF mm)]2/12.56]. Most recent percent predicted forced expiratory volume in 1 second 
(FEV 1%) was obtained from each patient's medical record. 
Patients were then sent to the University of Utah Medical Center to have bone 
scans completed. The dominant arm's radius and ulna bone mineral contents (BMC), 
BMD, and bone areas were measured with the Norland p-DEXA portable machine 
(Norland Corp. , Fort Atkins, WI). The lumbar spine (L2-L4) BMC, BMD and bone area 
were measured using the Norland XR-26 DEXA bone absorptiometer. The accuracy 
error for determining bone mineral mass is <l% and the long-term precision error for 
both machines is <0.5%.6 
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BMCs were reported in grams, BMDs in grams per cm2, and bone area in cm2• 
Currently, there are no evidence-based guidelines for classification of bone health in 
children. T scores are used for classification in adults, but because these patients have 
not reached their peak bone mass, T scores (standard deviations (SDs) in relation to sex 
matched peak BMD) were not appropriate for this young group. Therefore, z scores (the 
number of SDs that a BMD measurement is from the mean of an age and sex matched 
control population) were the best alternative. Spine BMD results were expressed as z 
scores to minimize the effects of age and sex. Appropriate reference data for these age 
groups could not be found for the other BMD measurement sites. This is probably due to 
the fact that technologic improvements in bone health assessment have out-paced 
pediatric research in this area. 
SPSS version 10.0 was used to analyze the data (SPSS Inc. 1998, version 10, 444 
N. Michigan Avenue Chicago, IL 60611). When t-tests were utilized, Levene's Test was 
used for equality of variances. Pearson Correlations were used to examine associations 
between variables. For all tests , significance was based on a two-tailed test at the 0.05 a 
level. Trends were based on a two-tailed test at the 0.10 a level. 
Results 
Demographics and Anthropometries 
The anthropometric and demographic characteristics of the participants are 
reported in Table 1. The average age of the CF and control pat1icipants was 8.7 years 
(+/-2.8 years) and 8.4 years (+/-2.9 years), respectively. The healthy non-CF controls 
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had significantly higher means for height for age percentile (p=O.OOO) and weight for 
age percentile (p=O.OOO). The mean values for the control group were also significantly 
higher for measures of arm muscle and fat in terms of percentile for age, including mid-
arm circumference (p=O.OOO), arm muscle circumference (p=O.OOO), arm muscle area 
(p=O.OOO), triceps skinfold (p=O.OlO), and subscapular skinfold (p=0.028) as shown in 
Table 1. The two groups did not significantly differ in their mean values for weight for 
height percentile, BMI or chest circumference. The CF participants' mean FEY 1% value 
was 98.4 (SD+/-15.8), which is in the normal range. 
Table 1 
Anthropometric and demographic characteristics 
Age, yrs 
FEY! % 
BMJ 
Ht %ile group* 
Target ht %ile group* 
Wt %ile group* 
Wt/ht %ile group* 
MAC %ile group** 
AMC %ile group* * 
AMA %ile group** 
TSF %ile group** 
SS (nun) 
CF 
N 
51 
46 
51 
51 
51 
51 
44 
51 
51 
51 
50 
46 
Mean +I-SD N 
8.7 +/- 2.8 32 
98.4+1-15.8 (N/A) 
16.4+1- !.5 28 
3.3 +I- J .8 32 
5. 1+1- 1.2 30 
3.8+1- 1.3 32 
4.7+1-1.2 23 
7.6+1-4.6 3 1 
9.6+1-5.0 31 
9.5+1-5.0 29 
6.5+1-4 .3 31 
5.8+1-2.2 31 
* 1=<5%, 2=5-< 10%, 3=10-<25%, 4=25-<50%, 5=50-<75%, 6=75-<90%, 7=90-<95%, 8=>1=95% 
**1=<5%, 2=5-<10%, 3=10-< 15% .. 18=85-<90%, 19=90-<95%, 20=>1=95% 
'p<0.03 
'p<O.OI 
Controls 
Mean +I-SD 
8.3+/-2.7 
16.9+1-2.2 
4.7+1-1 .8b 
5.5+1- 1.7 
5. 1+1- 1.6b 
4. 9+1- 1.5 
l 3.5+1-5.0b 
14.7+1-4.6b 
J4.6+1-4.8b 
9.8+1-6. J b 
7.5+1-3.7" 
Anthropometric variables that positively correlated with spine BMD z scores in 
the CF group were height and weight for age percentiles (r=.325, p=.021 and r=.366, 
p=.009 respectively) as well as MAC (r=.404, p=.004), AMC (r=.379, p=.007), and AMA 
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(r=.386, p=.006) percentiles. The control group showed a significant correlation for 
weight for age percentile and weight for height percentile with spine BMD z score 
(r=.379, p=.033 and r=.431, p=.040, respectively). There was also a correlation between 
BMD z score and MAC (r=.485, p=.006), AMC (r=.482, p=.006), and AMA (r=.507, 
p=.005) percentiles. 
Dietary Intake 
See Table 2. Although the CF group in this study easily exceeded general dietary 
intake recommendations for healthy individuals for the nutrients of interest in this study 
(protein, calcium, vitamin D, phosphorus, and magnesium), they just barely exceeded the 
recommended dietary allowance (RDA) for calories and did not meet the Cystic Fibrosis 
Foundation's (CFF) recommendations for caloric intake. The CFF generally 
recommends 120-150% of the RDA for energy needs, while this CF group had a mean 
caloric intake of 105% of the RDA (SD 28). The controls ' mean was 60% of the RDA 
with an SD of 18. 
In the control group (also in Table 2), there was a significant correlation (r=0.420, 
p=0.033) between percent dietary reference intake (DR1) calcium intake and spine 
density z score. There were no significant dietary correlates with spine BMD z score in 
the CF group. The controls had only a slightly higher mean self-reported activity level 
(3.1 vs. 2.8 on a scale of 0-5), and the difference was not significant. 
Bone Measurements 
Six CF participants and two controls had a history of previous fracture. None of 
these fractures were diagnosed as atraumatic, and none of these participants had spine 
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Table 2 
Usual daily intake (per 3-day diet record) and activity 
%RDA for Calories 
kcals/kg 
%RDA for protein 
grams protein/kg 
%DRJ for calcium 
%RDA for vitamin D 
%DRI for phosphorus 
%DRI for magnesium 
Activity*** 
*p<0.02 
**p<O.O I 
N 
39 
39 
39 
39 
42 
39 
42 
40 
40 
CF 
Mean +I-SD 
105+/- 28 
82+/-24 
276+/-90 
3. 1+1-1.0 
183+/- 178 
157+/-79 
271+/-317 
254+/-638 
2.8+/-0.7 
***on a scale of 0-5 (O=bed rest, 5=strenuous, sustained exercise) 
Controls 
N Mean +I-SD 
26 60+/-18** 
26 92+1-27 
26 224+/-59** 
26 2.1+/-0. 5** 
26 94+1-30** 
26 111+/-52** 
26 143+1-53* 
26 I 08+/-35 
23 3.1 +1-0.8 
BMD z scores less than or equal to -1.0. Table 3 shows the means for BMD, BMC, and 
spine area. There were no significant differences between the means for the control and 
CF groups for any of these raw values. When broken down by gender and age groups, 
there were still no significant differences. The CF patients' mean BMDs were slightly 
higher for all three of the values noted , as well as the BMCs for both arm measurements. 
The control group had slightly higher means for the spine BMC and spine area. The 
spine z scores showed a slightly different picture than the raw BMD scores. The CF 
group had a negative mean z score (-0.001); the control group had a positive score 
(0.079), with the difference nearing significance (p=0.55). 
Within the CF group, the difference between the males' and females' spine BMD 
z scores neared significance (p=0.062), with females having a positive mean spine 
density z score and males had a negative mean score. When broken down into age and 
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Table 3 
Bone mineral density (g/cm2), bone mineral content (g), spine area (cm2) and spine z score 
CF Controls* 
N Mean +I-SD N Mean +I-SD 
Distal radius+ulna BMD 50 0.217+1-0.045 32 0.208+1-0.050 
Proximal radius+ulna BMD 50 0.449+1-0.098 32 0.435+1-0 .095 
Lumbar spine (L2-L4) BMD 50 0.588+1-0. 107 32 0.572+1-0.0 11 
Distal radius+ulna BMC 50 0.583+1-0. 186 32 0.567+1-0.021 
Proximal radius+ulna BMC 50 0.966+1-0.296 32 0. 942+1-0.029 
Lumbar spine (L2-L4) BMC 50 16.62+1-6.07 32 17. 15+1-7.1 7 
Spine area (L2-L4) 50 27.54+1-6.00 30 29.33+1-6.63 
Lumbar spine (L2-L4) z score 50 -.0 12+1-.594 30 .079+1-.755 
*no significant differences between means 
gender groups, both the control and CF groups had a negative spine BMD z score for 
females ages 10 through13 and males ages 7 through 9. 
Lab Values 
Serum and urine samples were obtained from 40 of the CF participants (see Table 
4). Serum 25(0H)D, the inactive form of vitamin D, was positively correlated (r=0.432, 
p=0.005) with spine density z score, BMI (r=0.417, p=0.007), height percentile group 
(r=0.334, p=0.035), and weight percentile group (r=0.426, p=0.006). Surprisingly, serum 
25(0H)D was negatively correlated with serum vitamin A, another fat-soluble vitamin 
(r=-0.466, p=0.002). Serum I ,25(0H)2D significantly correlated with serum PTH 
(r=0.358, p=0.029), as would be expected, but not with anything else. 
Fat-soluble vitamin levels were generally low to normal (see Table 4) in the CF 
participants. More than half had low serum vitamin A levels and almost one third had 
low vitamin E levels. Very few participants had low levels of 25(0H)D. Vitamin A 
levels were negatively correlated with BMI (r=-0.339, p=0.033) and PTH (r=-0.336, 
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Table 4 
Serum and urine laboratory values (CF patients) 
Below norm Within norm Above norm 
S Calcium I 38 I 
S Magnesium 5 32 3 
S Phosphorus 7 33 0 
S 25(0H) vitamin D 2 36 2 
S 1,25 (OHh vitamin D 5 24 9 
S Parathyroid hormone 2 22 14 
S vitamin A 26 14 0 
S vitamin E 12 28 0 
S Alkaline phosphatase 13 25 I 
U Calcium 4 27 9 
U Sodium (N/A)* 
U Creatinine (N/A)* 
U Hydroxyproline (NIA)* 
*Normal reference values not available/applicable 
p=0.039) and positively correlated with vitamin E levels (r=0.338, p=0.033). Alkaline 
phosphatase, a nonspecific measure of bone formation , was below normal levels in more 
than one third of CF participants. Alkaline phosphatase levels were negatively correlated 
(r=-0.405, p=0.012) with serum PTH levels. 
Fourteen (37%) of the participants had elevated serum PTH, although only one 
had low serum calcium. As already mentioned, PTH was positively correlated with 
serum 1,25(0H) 2D. There was a weak positive correlation (r=0.305, p=0.063) between 
PTH and spine density average z score. For further analysis, the CF participants were 
divided into quartiles based on their PTH values. The top quartile had significantly 
higher ( -0.3824 vs. 0.4099, p=0.017) spine density z scores than the bottom quartile. 
PTH was also positively correlated with AMC percentile (r=0.439, p=0.006) and AMA 
percentile (r=0.443, p=0.005). 
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Discussion and Conclusons 
Demographics and Anthropometries 
The CF population used in this study had mild disease severity compared to 
national averages and groups used in comparative studies. The CFF reported a range 
mean FEY 1% of approximately 95% to 80%, respectively, for children ages 6 up to 13.5 
years.' Our study included children ages 3-13.5 years and their mean FEY 1% score was 
98% (SD 16), which is considered normal,4 and is a relatively high value, even for a 
young CF group like this one. Unlike Henderson and Madsen 7 and Haworth et al.,8 we 
did not find a relationship between BMD z scores and FEY 1%. Perhaps this was because 
most of our population had normal FEY 1% scores and BMD z scores. Haslam et al.9 also 
did not find a relationship between FEY 1% and BMD z scores in their children with CF. 
It has often been hypothesized/stated that CF patients are less active than 
individuals without CF and that this may be a factor in decreased bone density. Although 
the control group had a slightly higher mean activity level than the CF group, the 
difference was not significant. This agrees with the findings of Grey et al. 10 The only 
variable that activity level correlated with in either group was serum PTH in the CF 
group (r=0.394, p=0.028). 
There was no significant difference between the groups' mean target height 
percentiles. As expected, height and weight for age percentile groups were lower in the 
CF group, but not weight for height percentile groups. There was also no significant 
difference between the groups' mean BMis. McNaughton et al. 11 found the same results 
in their study of 226 children with CF. Generally, a decreased height for age along with a 
decreased weight for age is indicative of chronic malnutrition, and decreased weight 
for height indicates acute malnutrition. This may indicate that this CF population is 
mildly stunted and underweight, but not wasted. 
Dietary Intake 
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The CF group had significantly higher nutrient intakes than the control group, as 
was seen in Mortensen and colleagues' study, 12 which was done in the same geographical 
area as our study. The higher intakes in the CF group as opposed to the control group 
(per percent of recommendations) of calories (75% higher in CF group, p=O.OOO), 
calcium (95% higher in CF group, p=0.003), protein (23% higher in CF group, p=0.007) 
and vitamin D (41% higher in CF group, p=0.005) may have had a protective effect on 
bone density as well as preventing nutritional wasting and severe growth stunting, which 
would additionally promote bone growth and strength. 
It has been recommended 13 that CF children's and adolescents' calcium intake 
levels should at minimum meet levels specified by the 1997 Institute of Medicine 
National Academy of Science, Food and Nutrition Board. 14 The standard used for this 
study (DRI) meets or exceeds those recommended intake levels for each of the age 
groups represented in this study. 
It is widely accepted that the CF population has greater nutrient needs, including 
that of calcium, than does the general population. While the CF group generously 
exceeded the DRI for calcium (183%), we do not know, at this time, a lot about the CF 
population's or CF individuals' actual calcium needs. Long-term studies that follow 
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calcium intake, pertinent lab values and bone growth may be necessary to better assess 
needs and judge intake levels for this population. 
Lab Values 
Serum alkaline phosphatase levels were low in more than one third of the CF 
patients. Alkaline phosphatase is an indicator of bone remodeling activity and turnover, 
although it is only a crude indicator because it is also associated with the liver. For future 
research, newer tests, like bone specific alkaline phosphatase, are becoming more 
affordable and give a better indication of what is going on specifically in bone. 
It was interesting that, although it was weak and not significant, we found a 
positive correlation between PTH and spine density average z score. Other researchers, 
like Haworth et al.,8 have reported a negative relationship between BMD z score and 
PTH. One other group of researchers, Bhudhikanok et al. 15 also found a positive 
correlation between serum PTH and lumbar spine BMD. There is currently a great deal 
of research being done on the use of PTH as an anabolic agent in bone metabolism.16-24 
Although there is evidence of PTH having net anabolic effects on bone, it is achieved 
through short-term intermittent injections once or twice daily, not sustained high levels 
produced in the body over a long period of time as would most likely be the case in 
secondary hyperparathyroidism. Secondary hyperparathyroidism is believed to lead to 
net bone deficits over time. Checking PTH levels periodically may be helpful in 
identifying individuals at risk for vitamin D deficiencies. Depending on PTH and 
vitamin D levels, a bone scan may be indicated as well. 
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Serum calcium levels are strictly controlled by the body ' s efficient homeostasis 
mechanisms, so it may not be surprising that serum calcium levels did not correlate with 
BMD. Therefore, serum Vitamin D metabolites should give us better information about 
possible nutrient deficiencies and bone metabolism in general. The two different 
measures of vitamin D used were 25(0H)D and 1,25(0H)2D. Inactive vitamin Dis first 
metabolized by the liver to 25(0H)D and then by the kidneys to the active 
form,l,25(0H)2D (calcitriol). When there is vitamin D deficiency, PTH levels rise and 
subsequently cause the production of more calcitriol. Nine out of 38 of our CF 
participants had elevated serum 1,25(0H)2D, while 14 had elevated PTH. 
Serum 25(0H)D may be a better indicator of vitamin D stores than I ,25(0H)2D, 
because serum 1 ,25(0H)2D levels decline only in severe deficiency when 25(0H)D 
levels are already depleted. Although only two participants had low 25(0H)D levels 
according the normal reference range used, several more patients may have had 
suboptimal levels, as indicated by elevated PTH and 1 ,25(0H)2D. Surprisingly, neither 
of the CF participants with low 25(0H)D levels had elevated PTH levels, but both did 
have negative spine density z scores (-0.73 and -0.47). 
We found a positive correlation between 25(0H)D and spine z score, quite 
possibly indicating the need to keep 25(0H)D levels at desirable levels. Poor absorption 
and/or utilization of oral intake of vitamin D may play a role in the development of 
osteoporosis in CF. Lark and colleagues' studi5 of 10 subjects with CF and 10 healthy 
controls showed that even with the use of supplemental pancreatic enzymes, CF subjects 
absorbed less than half of the vitamin the controls did. Additionally, rises in 25(0H)D 
levels were significantly lower in the CF group over time, which may suggest that 
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vitamin D conversion rates are reduced in CF subjects. This study also showed a high 
variability in CF subjects' absorption rates, with two subjects showing virtually no 
absorption. All CF patients at this clinic were prescribed daily supplements of vitamins 
A, D, E and K at age-specific levels suggested for children with CF by the CFF, but this 
may not be adequate. Vitamin D levels should be checked at least once or twice per year. 
If oral supplementation of vitamin D is inadequate to sustain serum levels, parenteral 
administration of vitamin D may be warranted. It may be helpful to check alkaline 
phosphatase (or bone specific alkaline phosphatase, if available) levels periodically, as 
well. 
Bone Measurements 
It is difficult to compare studies on bone density because there is no general 
consensus in the research community on the most appropriate equipment and technique to 
assess bone. DEXA is currently the method of choice for measuring bone density 
because it is noninvasive, painless, relatively inexpensive, and gives high precision with 
low radiation dose. However, it has been argued that DEXA is potentially problematic 
when measuring and assessing patients with smaller than average size for age, as is the 
case with cystic fibrosis. 
DEXA gives an areal BMD (grn/cm2), and not truly a volumetric (gm/cm3) 
measurement; therefore, it may underestimate bone mineral status in small bones. DEXA 
BMD is derived by dividing BMC within a defined region, in grams, by the projected 
area of the bone in cm2• This means that bone thickness is not factored into these 
estimates; therefore, the bone densities of short people are inherently underestimated. 
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Researchers have tried to correct this in various ways. For example, they adjust DEXA 
BMD results for height and/or weight or use an estimated total vertebral volume to 
calculate "bone mineral apparent density" (BMAD). The effectiveness/accuracy of these 
methods has not been adequately proven or agreed upon. In addition, DEXA machines 
cannot distinguish between cortical and trabecular bone or give any information on bone 
architecture. 
This pre-pubescent CF population did not significantly differ from controls in any 
of the measures of bone size or density used in this study. This agrees with the results of 
at least four other published studies,9' 12'26'27 which also used children that were "well 
nourished" or had "mild" disease. Two other studies28·29 were found that reported a 
decrease in bone density in pediatric CF patients. 
It is interesting to note the methods used to measure bone density in these 
comparative studies. Bhudhikanok et al. 15 used DEXA to measure density of the lumbar 
spine (L2-lA) just as we did. They also measured whole body and hip bone density. 
Because they were worried about the bone densities of the smaller CF patients being 
underestimated, they calculated BMAD z scores as well. The disease severity of their 
pediatric CF patients was difficult to determine because the pediatric and adult patients 
were combined when reporting many of the characteristics and results of subjects. 
Although they did not separate results based on age or adult versus pediatric groups, they 
did state that bone mineral was reduced with increasing age in the majority of CF patients 
at all sites measured- most notably at the femoral neck (hip). After adjusting for smaller 
bones with BMAD scores, they still found significant differences between the CF group 
and controls (again, no differentiation made between children/adolescents/adults). 
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Our CF patients were smaller than the controls. This means we could 
theoretically expect the bone densities of our patients to be under-estimated with DEXA, 
leading to a finding of decreased bone density in the CF patients compared to controls. 
However, we did not see a difference in spine BMD z scores between the groups. 
Therefore, calculating BMAD would have been redundant in our case. 
We cannot draw any conclusions about the disease severity of the children in the 
Bhudhikanok et al. 15 study, which may in large part account for the differences in our 
results. In addition, they studied 49 patients ages 8.4 to 48.5, with a mean age of 20.6 
years. Their actual pediatric population in the study could have been relatively small, as 
well as older than this study's pediatric group. 
The Gibbens et al. 29 study is noteworthy because they used computer tomography 
(CT) scanning to determine authentic volumetric BMD and to distinguish between 
cortical and trabecular bone. Trabecular bone is relatively prominent in the vertebrae (at 
approximately 70%) and hip (specifically, the intertrochanteric area), while the midshaft 
of long bones consists entirely of cortical bone.30 Because trabecular and cortical bone 
respond to stress and change differently, it may be especially important in disease states 
to study them separately. Cortical bone metabolism is controlled largely by hormones 
such as PTH and 1,25(0H)2D. 
Differences in skeletal sites studied may also account for some of the seemingly 
wide variances in the research on bone density in CF. There is no general consensus on 
which bone sites are best to measure in children with CF. Because different sites have 
different proportions of cortical versus trabecular bone, variances in exact site(s) 
measured could produce drastically different results. We measured the radius, ulna and 
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lumbar spine in our study. Whereas the radius and ulna are comprised predominantly 
of cortical bone, the vertebrae are prominently trabecular bone. Unfortunately, we were 
unable to find sufficient reference data on the radius and ulna sites that we measured. 
Although our data on the radius and ulna were not standardized, there were no 
significant differences in raw data averages for both BMD and BMC between the CF and 
control groups on these bones. None of the measurements done on the spine produced 
any significant differences between the groups, either (including the z score for L2-lA 
spine density). When broken down by gender or age group, the only significant 
difference found was a higher mean value for the area of lumbar two in the 10-13 year 
old controls versus the 10-13 year old CF participants. When the groups were broken 
down further by gender and age, the only significant differences found were between the 
males ages 3-6 groups (BMC of L2-lA and spine area of L2-lA) and the males ages 7-9 
groups (spine area of L2). These differences could be explained by the difference in 
height and weight for age between the two groups. 
In a review done on pediatric bone disease, Leonard and Zemel 30 reported that in 
their study of others ' research, they found no gender effect on bone density (cortical or 
trabecular) during childhood and adolescence, but they did in cross-sectional trabecular 
bone area (specifically, in the spine). Boys ' vertebral bodies were wider than girls ' , even 
when adjusted for height and weight. We found no significant differences between males 
and females within the CF or control group on any of the bone measurements. Nor were 
there any significant differences between males and females in raw height, weight or 
BMI averages in the CF or control groups. 
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Although not significant, in our study females in both groups had higher mean 
spine density z scores than males (nearing significance in the CF group with a p value of 
0.062). It is interesting to note that Bhudhikanok et al. 15 also found a significant 
difference between males and females in bone density of the lumbar spine, with female 
patients having significantly higher values. (Although, in their 1998 study, Bhudhikanok 
et al. 28 found no gender differences in BMD z scores in CF youth.) In addition, Jones and 
Dwyef' found in their study of 330 8-year-old children that males had higher size-
adjusted BMD at the hip; females had higher size-adjusted BMD at the spine. Therefore, 
our results may not be unexpected or unusual. 
Notable Individual Results 
In terms of individuals in this study, there were some noteworthy results. Low 
bone mass is generally defined as a BMD between 1 and 2.5 SD below a mean value for 
a given population. Goulding et al. 32 reported from their findings that each SD decline 
below the mean total body BMD for youth doubles the risk of fracture . In our study, 
there were two children in both the CF and control groups than had BMD z scores less 
than -1.0. 
The control group had the two lowest BMD z scores (see Table 5). Both of them 
were 6-year old females with low height and weight. One of them did not complete a 
3-day diet record or anthropometric measurements, but the other showed low dietary 
intake levels of calcium (61% DRI) and energy (66% RDA), and very low fat stores per 
TSF measurement (less than the 51h percentile). 
Table 5 
Characteristics of individuals with low bone density 
M, aoe 3 
ID# 34 20 73 
L2-lA BMD z score -1.07 -1.10 -0.01 -l.l7 
Ht %ile group* 5 3.3 2 
Target ht %ile group* 6 4 5. I 5 
Wt %ile group* 4 3 3.8 2 
Wt/Ht %ile group* 4 4 4.7 4 
AMC %ile group** 8 3 9.6 N/A 
AMA %ile group** 8 3 9.5 N/A 
TSF %ile group** 4 8 6.5 N/A 
FEY, % (too young) I 12 98.4 NIA 
S 1,25(0Hh vitamin D" 54 10 41.1 N/A 
S 25(0H) vitamin D" 20.5 25.0 33.6 N/A 
SPfH' 10 62 53.8 N/A 
S vitamin A" 56 39.5 51 N/A 
S vi tamin E' 16.5 12 .4 14.1 N/A 
S Alkaline g hosphata se' 93.5 28.4 64.6 N/A 
%RDA for Calories 117 150 105 N/A 
%DR! for calcium 238 274 183 N/A 
* I =<5%. 2=5-< I 0%, 3= I 0-<25%. 4=25-<50%, 5=50-<75%. 6=75-<90%, 7=90-<95%, 8=>1=95% 
** 1=<5%. 2=5-< 10%. 3= 10-< 15% .. 18=85-<90%. 19=90-<95%, 20=>1=95% 
' in pg/ml , normal reference range used = 18-62 
''in ng/ml , normal reference range used = 12-60. CFF proposed minimum = 30 
' in pg/m l. normal reference range used = 11 -54 
''in mg/ml , normal reference range used = 30-100 for ages l -5y, 60-100 for ages 5-16y 
' in mmol/1. normal reference range used = 10-2 1 for ages J-6y. 13-24 for >6y 
'In IU/ L, normal reference range used = 47- 112 
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-1.43 0.08 
4 4.7 
6 5.5 
3 5.1 
2 4.9 
12 14.7 
12 14.6 
9.8 
N/A N/A 
N/A N/A 
N/A N/A 
N/A N/A 
N/A N/A 
N/A N/A 
NIA N/A 
66 60 
61 94 
Both of the CF subjects with low spine bone density were males. One was 3 
years old, the other 8. Both exceeded calcium intake levels, but the 3-year old exceeded 
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CF recommendations for caloric needs while the 8-year old fell short. The 3-year old had 
close to average height and weight while the eight-year old was below the 5'h percentile 
on height for age and below the 25' 11 percentile on weight for age. 
Laboratory values varied between these two subjects. The only noteworthy labs 
on the 3-year old subject were low PTH and 25(0H)D levels (per CFF proposed 
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recommendations). Typically, one would expect to see elevated PTH if vitamin D 
levels were low. The 8-year old had several abnormal lab values, including low 
l,25(0H)2D, 25(0H)D (per CFF proposed recommendations), vitamin A, vitamin E, and 
alkaline phosphatase. PTH was elevated. These laboratory values could indicate 
malabsorption and consequent mild secondary hyperparathyroidism, which could be 
contributing to decreased bone density. He had good lung function, as evidenced by a 
high FEY,% score (112%). 
Conclusion 
Several other studies have shown differences in young adult/adult groups, and 
Bhudhikanok et al. 15 concluded from their research that "Osteopenia is common at all 
ages in cystic fibrosis ... " But this is still a point of debate and was the focus of our 
research. 
Pubertal development is often delayed in patients with CF, most likely due to 
growth failure and poor nutritional status. We studied prepubertal children to help 
determine exactly when bone loss, or slowed/inadequate bone gain, begins. It is fairly 
well established that osteopenia is prevalent in adults with CF, but there is more debate 
regarding younger patients. Because the pubertal period is so important in achieving 
peak bone mass, delayed pube11y may decrease the final peak bone mass attained, and 
therefore, be at least one of the factors that leads to decreased bone density in adults with 
CF. Our results could suppo1t this theory. 
Disease severity is another factor of interest based on our results. Because our CF 
group was young and had mild disease, another contributing factor to bone deficits could 
33 
be the advancing disease severity as patients age. Several researchers8•10•15•29 have 
shown a correlation between FEY 1% and bone density, but these were seen in older 
groups with more advanced disease. We may not have seen this relationship because our 
CF group was generally healthy with good FEY 1% scores and bone densities. Again, 
different bone sites may react differently to the stress of disease (and diet, exercise, 
biochemical serum levels, etc). 
Perhaps different sites in the body where bone is a higher proportion of cortical 
bone would have shown more of a difference. Future studies should obtain multiple sites, 
possibly including spine, arm, hip, and femur. Although not as practical as DEXA in 
most circumstances, a whole body QCf (quantitative computed tomography) scan may 
give us the best information in future research. QCf is costly and high radiation 
exposure is a concern with this technique, but new technology is finding safer 
alternatives. Peripheral QCf, which uses high resolution scanners for the peripheral 
skeleton may be an option.30 As more knowledge and data are added to this body of 
research, we will be better able to standardize and compare results. 
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Abstract 
CHAPTER 3 
THE EFFECf OF FORTIFIED MILK ON BONE DENSITY 
IN CHILDREN WITH CYSTIC FIBROSIS 
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Aim--To compare bone density in children with Cystic Fibrosis (CF) and healthy children 
without CF, and to determine clinical correlates of bone density in both groups. 
Methods-In 51 children with mild CF and 32 controls (ages 3-13), bone mineral density 
(BMD) of the lumbar spine (L2-lA) and proximal and distal radius and ulna were 
measured at baseline and at least three months later using dual energy x-ray 
absoptiometry (DEXA). The CF group was divided into two groups, one of which drank 
a milk product fortified with double the normal amount of calcium and vitamin D three 
times daily for three months. The other CF group drank a non-fortified milk product. The 
relation between BMD and anthropometrical measurements, dietary intake, biochemical 
indices, lung function , activity level, enzyme and vitamin usage, and malabsorption 
symptoms were studied. 
Results-Although the CF group was significantly lower in weight-for-age and height-
for-age than the controls, they did not significantly differ from the controls in any 
measures of bone density. Both the CF and control groups had significant increases in 
spine BMD z score over the course of the study. The CF group had significantly higher 
dietary intake of calories, protein, calcium and vitamin D than the control group at 
baseline. In the control group, there was a significant correlation between calcium intake 
and spine density z score. There were no significant differences between the regular and 
37 
fortified CF milk groups in any bone measurements. In the CF group, serum 25 
hydroxyvitamin D (25(0H)D) levels were positively correlated with spine density z 
scores. Proper enzyme usage was correlated with malabsorption symptoms. 
Conclusions- There were no bone deficits in this pre-pubescent CF population. While 
no dietary correlates for BMD were observed in the CF children, sup-optimal intakes or 
malabsorption, as well as worsening disease severity with age, may contribute to deficits 
over time. While increasing calcium intake did not appear to increase bone density in 
this group of children with CF in the given length of time, the protective effect of calcium 
cannot be ruled out and should be studied in other age groups at varying levels of intake. 
38 
Introduction 
Great advancements in CF care have occurred in recent years. From 1985 
through 2001, predicted survival for CF patients increased from about 25 years of age to 
about 33 years of age. 1 This increase in life span has led to the development of a new set 
of long-term complications. These include diabetes, liver disease, malnutrition, 
suboptimal growth, infertility, and osteopenia.Z Osteopenia in CF patients can lead to 
premature osteoporotic fractures which decrease quality of life and increase medical 
costs. 
There are several pathogenic factors of CF that could contribute to the risk for low 
bone density. Potential risk factors include delayed puberty in adolescents, 
hypogonadism in adults, chronic use of corticosteroid medications for lung disease, 
inadequate amounts of weight-bearing physical activity and disease severity. 
Many correlated risk factors, like pancreatic insufficiency and suboptimal growth, 
are related to poor nutritional status. Eighty-five to 90% of children with CF have 
exocrine pancreatic insufficiency,3 which leads to malabsorption of dietary nutrients 
(including calcium, magnesium, and vitamins D and K). Although pancreatic enzyme 
replacement therapy is used to treat this, even optimal use of enzymes cannot fully 
compensate for pathogenic deficiencies. Standard nutritional recommendations (for both 
energy intake and specific nutrients) for CF patients are higher than that of healthy 
populations, but it is nearly impossible to precisely determine nutrient needs for 
individuals in various stages of growth and disease progression. Malabsorption can lead 
to undernutrition and resulting suboptimal growth. It could also theoretically decrease 
peak bone mass (due to both suboptimal growth and malabsorption of bone 
metabolism-related nutrients, specifically calcium and vitamin D). 
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Much of the research done on bone density in CF is carried out with adult groups 
or combined youth and adult groups, in which children/prepubescent youth are not 
considered separately from adult/pubescent youth. This study is unique in that only pre-
pubescent children with CF (and matched healthy controls) were recruited for the study 
in significant numbers. This research could be especially important because the 
prepubertal period may be an ideal time for preventive measures to be implemented. 
This study is also unique in that it is an intervention study. No other published 
study was found at the time this study was done that implemented any kind of treatment 
or preventive measure in the study of bone density in CF. The intervention used in this 
study was a fortified milk product. 
The purposes of this study are to evaluate the differences in bone mineralization 
between children with CF and healthy control children over a 3-month period, and to 
determine which clinical variables can be used as predictors of risk for BMD deficits in 
CF. The effect of calcium and vitamin D-fortified milk on bone density in children with 
CF will be evaluated. The results of this study may be beneficial in the development of 
clinical screening tools and preventive measures for CF patients at risk for osteopenia. 
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Methods 
Sample Selection 
This study was approved by the University of Utah Medical Center's Institutional 
Review Board (IRB) and Utah State University's (USU) IRB before participants were 
enrolled. Study participants were recruited from the Intermountain Cystic Fibrosis 
Center's clinic at Primary Children's Medical Center (PCMC) in Salt Lake City, Utah. 
This center serves children with Cystic Fibrosis (CF) from Utah, Idaho, Wyoming, and 
Nevada. At the beginning of this study, the CF clinic roster showed approximately 150 
patients aged 2 to 16 years enrolled at the clinic. A letter describing the study, its 
purpose, qualifications, and possible benefits of enrollment (see Appendices A and C) 
was sent to all qualified patients, inviting them to participate in the study. Additionally, 
this letter included a request for referrals of healthy children without CF to serve as 
controls in the study (see Appendices B and C). Healthy controls were also recruited 
through advertisement within PCMC. 
Fifty-one children with CF and 32 healthy controls (20 of these were siblings of 
CF participants) enrolled in the study. A signed informed consent (see Appendices D and 
E) and, when appropriate per patient's age, assent (see Appendix F) form was obtained 
for each participant. All CF participants were to continue all treatments prescribed by 
their physician, including pancreatic enzymes, medications, and routine vitamin and 
mineral supplements per CF clinic protocol.4 
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Data Collection 
Participants with CF were stratified by age (ages 3-6, 7-10, and 11-16) and sex 
and paired with a control participant. Most recent percent predicted forced expiratory 
volume in 1 second (FEY 1%) score using Knudson equations5 was obtained for each CF 
participant. The Knudsen equations are categorized as severe (<40%), moderate (40-
69%), mild (70-89%), or normal(>/= 90%).5 The participants in each CF pair were 
randomly assigned to either the treatment (fortified milk) or control (regular milk) group. 
Because several families had to travel from either another city or state to attend CF clinic, 
volunteer participants began the study on their next scheduled routine follow-up 
appointment. Follow-up appointments were routinely scheduled every 3 months. Per 
Dr. Gary Chan at the University of Utah Medical Center, a change in bone mineral 
accretion can be detected in that time frame, so subjects were to participate in the study 
for 3 months. The range of dates for beginning the study were 11/09/1998 through 
0611011999, and the range of dates for completing the study was 01/26/1999 through 
09/1511999. 
The CF participants began the study on the next regularly scheduled follow-up 
appointment. Control subjects made an appointment with the graduate student, a 
registered dietitian, and bone scan lab. On day 1 of the study, it was explained in-depth 
by the graduate student, and any questions the participants or their parents had were 
answered before the consent/assent forms were signed (see Appendices D, E, and F). 
Preliminary data was obtained on the patients, including history of bone fractures 
(number, location[s] and cause[s] of) and biological parents' self-reported heights (see 
Appendices G and H). 
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The CF participants brought a urine sample (first of that morning) in a 
sterilized container kept on ice. It was frozen for later measurement of calcium, sodium, 
creatinine, and hydroxyproline. A serum sample was also obtained and frozen for later 
measurement of calcium, magnesium, phosporus, 25(0H)D, 1,25 dihydroxyvitarnin D 
(1,25(0H)2), parathyroid hormone (PTH), vitamin A, vitamin E, and alkaline 
phosphatase. Urine and serum samples were not obtained from the controls, due to 
budget constraints, so normal reference values were used for comparison instead. 
Participants and their parents were instructed on how to keep a 3-day diet record 
(see Appendices I and J), which was to be completed the following 3 days before they 
began drinking the study milk. Diet records were returned by mail to the graduate 
student and analyzed using Nutritionist IV (Nutritionist IV Diet Analysis, 1995 version 
4.1, First Data Bank 1111 Bay hill Drive San Bruno, CA 94066) to evaluate intake of 
calories, protein, thiamin, vitamin D, vitamin K, calcium, phosphorus, and magnesium. 
They were also instructed on how to complete log sheets (see Appendices K and L). Log 
sheets were to be completed daily for the duration of the study and mailed weekly to the 
graduate student. Malabsorption symptoms, intake of high calcium foods, proper enzyme 
usage, vitamin/mineral supplementation, and activity level for each day were tracked via 
these forms. An information sheet on malabsorption was also given to participants to 
encourage use of prescribed enzymes (see Appendix M). 
During the course of their regular follow-up visit for clinic that day, 
anthropometric measurements were taken by the clinic's registered dietitian. Weight was 
measured on a calibrated platform scale and height with the use of a stadiometer. Body 
mass index (BMI) was calculated using height and weight (kg/m2). Mid-arm 
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circumference (MAC) and chest circumference (CC) were measured using a standard 
tape measure. Triceps skinfold (TSF) and subscapular skinfold (SS) measurements were 
determined with a Lange caliper, accurate to +1-lmm. De Meer et al.6 found skinfold 
measurements to be an appropriate tool in monitoring fat-free mass in all children with 
CF. Arm muscle circumference (AMC) was calculated using MAC and TSF [MAC-
(TSFmm):rt]. Arm muscle area (AMA) was calculated using MAC and TSF [[MAC-
:rt(TSF mm)f/12.56]. 
Patients were then sent to the University of Utah Medical Center to have bone 
scans completed. The dominant arm's radius and ulna bone mineral content (BMC), 
BMD, and bone areas were measured with the Norland p-DEXA portable machine 
(Norland Corp., Fort Atkins, W1). The lumbar spine (L2-lA) BMC, BMD and bone area 
were measured using the Norland XR-26 DEXA bone absorptiometer. The accuracy 
error for determining bone mineral mass is <l %, and the long-term precision error for 
both machines is <0.5%.7 
BMCs were reported in grams, BMDs in grams per cm2, and bone area in cm2• 
Currently, there are no evidence-based guidelines for classification of bone health in 
children. T scores are used for classification in adults, but because these patients have 
not reached their peak bone mass, T scores (standard deviations (SD) in relation to sex 
matched peak BMD) were not appropriate for this young group. Therefore, z scores (the 
number of SDs that a BMD measurement is from the mean of an age and sex matched 
control population) were the best alternative. Spine BMD results were expressed as z 
scores to minimize the effects of age and sex. Appropriate reference data for these age 
groups could not be found for the other BMD measurement sites. This is probably due to 
the fact that technologic improvements in bone health assessment have out-paced 
pediatric research in this area. 
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Once all of the baseline data was obtained, the CF participants were given 3 
months' worth of milk product (see "Description of Milk Product", below). The study 
milk product was described and additional information on the milk was given to patients 
and their parents (see Appendix N). CF participants were to drink 8 oz of this milk three 
times each day for the duration of the study. Control subjects did not drink this milk 
product, nor were they to make any dietary changes during the period of the study. 
There were several reasons that a whole milk product was used to administer the 
calcium to pa11icipants. First, it has been advised that 60% of the recommended daily 
allowance (RDA) of calcium be dairy calcium.8•9•10 Second, in CF clinic, the patients are 
strongly encouraged to drink whole milk, as it is a good source of calories, protein, 
calcium, vitamin D and other vitamins and minerals. We wanted to reinforce this, as well 
as provide an "intervention" that many of the participants were already using. Because 
the study population is a juvenile one, it was predicted that flavored whole milk would be 
more palatable and accepted and more easily taken by children (especially the very young 
children) than a pill. A third reason to use whole milk as the source of calcium was that 
many of these children are already taking several pills/medications as part of their CF 
treatment, and any additional pill may have decreased compliance for this study or made 
the study burdensome for some children. There is no conclusive data that there is better 
absorption of calcium from milk versus other sources, but milk does contain lactose and 
casein phosphopeptides, which may enhance calcium absorption and mineral retention. 11 
45 
Follow-up letters (see Appendix 0) were sent to participants as needed through 
the duration of the study to ensure diet records and daily logs were kept and sent to the 
graduate student. Upon completion of the study, participants returned to PCMC to repeat 
the same anthropometrical and bone density measurements made at the beginning of the 
study. 
Description of Milk Product 
Two flavors (chocolate and vanilla) of ultra high temperature (UHT) whole milk 
(manufactured by Gassner's in Logan, Utah) were used for this study. The milk was 
packaged in sterile 8-oz boxes with drinking straws attached to them. The boxes were 
white and unmarked, except for a letter code stamp, to blind the participants from 
knowing the type of milk they were assigned to consume. This type of milk was chosen 
because it does not require refrigeration and has a long shelf life (11 months), making it 
more practical for participants to take 3 months' worth of milk home with them the day 
they started the study. It also allowed for better compliance by making it more 
convenient for participants to drink three boxes each day, whether at home, school, or on 
vacation. 
Two popular flavors (as determined by a taste panel in the CF clinic) were used to 
help increase acceptance of milk product by children in the study. Vanilla and chocolate 
flavoring were used and produced milks of very similar nutritional content. Participants 
were given six cases (with 27 boxes of milk per case or 162 cartons) of each flavor unless 
otherwise requested. 
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The milk was fortified to double the amounts of both calcium and vitamin D 
normally found in 8 oz of Gossner's UHT milk (see Table 6). The calcium fortifier used 
was Lactoval QM (LQM) Calcium Complex (manufactured by DMV International 
Nutritionals, The Netherlands). LQM is 24.5% calcium and also includes phosphate 
(36.2%) citric acid (18.6%), sodium (2.7%) and trace amounts of other minerals. It also 
contains small amounts of protein ( 1.0% ), moisture (5.5% ), lactose ( 1.0%) and fat 
(0.4%). This calcium fortifier was chosen due to its compatibility with milk. It has a 
high solubility, bland flavor, neutral odor, smooth mouth feel, slow sedimentation in 
liquids, and a particle size of 95%<9 urn (DMV International Nutritionals, The 
Netherlands). LQM was added to the whole milk at a ratio of 5.225 gm LQM powder per 
kg milk. Each box of finished milk was approximately 240 gm or 8 oz. 
The formulation and testing of the milk product was done at USU. Eight ounces 
of Gossner UHT milk regularly contains 100 International Units (IU) (equal to 2.5 
micrograms) of vitamin D, which was doubled to 200 IU (5 micrograms). This totaled 
600 IU per day of vitamin D for the children on the fortified milk. The PCMC CF clinic 
recommends 400-800 IU per day. 
Because some settling of the calcium fortifier was possible, calcium analysis was 
done periodically (by USU Analytical Laboratories, Logan, UT) throughout the duration 
of the study. Through these analyses, it was found that a significant amount of the 
calcium settled out of the fortified vanilla milk throughout the duration of the study (see 
Table 6). 
Table 6 
Calcium content of study milk 
Code Key 2/5/99 5114199 
Name Milk Anal ysi s* Milk Analysis* 
E Fortified chocolate 552 504 
we Regular chocolate 264 240 
D Fortified vanilla 408 264 
c Regular vanilla 240 240 
*Amount of calcium in mg per 240 gm milk (amount in each 8 oz box) 
**Unable to complete analysis 
6/8/99 
Milk Analysis* 
528 
240 
360 
240 
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11/1/99 Average of 
Milk Analysis* Analyses* 
528 528 
** 248 
240 318 
240 240 
The amount of each flavor and the time period in which it was consumed were 
taken into account when possible for each participant. This was done by noting the time 
period in which the patients on fortified milk participated in the study (and using the 
corresponding values for calcium found in the fortified vanilla milk during that time 
period, using an average of multiple time periods if needed) and also taking into account 
what proportion of chocolate versus vanilla fortified milk the participant drank. In 
addition, not all participants drank the full amount of milk that they were instructed to 
drink. If the study milk was not consumed, participants were to report how much they 
did drink and when they drank it. Phone calls to remind participants to complete and 
mail in daily logs (enzyme use and calcium intake) were made monthly. 
Statistical Analyses 
SPSS version 10.0 was used to analyze the data (SPSS Inc. 1998, version 10, 444 
N. Michigan Avenue Chicago, IL 60611). When t-tests were utilized, Levene's Test was 
used for equality of variances. Pearson Correlations were used to examine associations 
between variables. For all tests, significance was based on a two-tailed test at the 0.05 a 
level. Trends were based on a two-tailed test at the 0.10 a level. 
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Results 
Demographics and Anthropometries 
The anthropometric and demographic characteristics of the participants are 
reported in Table 7. The average age of the CF and control participants was 8.7 years 
(+/-2.8 years) and 8.4 years (+/-2.9 years), respectively. The mean length of participation 
(time between initial bone density scans/anthropometrical measurements and final ones) 
in the study was 20 weeks ( +1-9.5 weeks) for the CF participants and 17 weeks ( +1-5.0 
weeks) for the controls. For a report of baseline data, see Chapter 2 Results (page 19). 
Over the course of the study period, the CF and control groups' anthropometrical 
means changed differently (see Table 7). Although the changes weren't significant, the 
CF group's mean height percentile group slightly declined, while the control's increased 
slightly. The CF group ' s weight for height percentile mean value went slightly up 
(p=0.059) while the control group 's went slightly down (p=0.835). The means for the CF 
group's TSF and MAC percentile groups and SS measurements went up significantly 
(p=0.035, 0.005 and 0.042, respectively), but the control group's did not change 
significantly. While the weight percentile group means remained virtually unchanged for 
both groups, the control group saw a greater increase in height, although not significant. 
Relationships between changes in arm fat and muscle stores differed between the 
CF and control groups. Change in the CF group's TSF percentile group negatively 
correlated with change in AMA (r=-0.381, p=0.017) and AMC (r=-0.373, p=0.019) 
percentile groups. In the control group, change in TSF percentile group positively 
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Table 7 
Initial and final anthropometric and demographic characteristics 
CF Controls 
N Mean +I-SD N Mean +I-SD 
Start age, yrs 51 8.7 +1-2.8 32 8.3+1-2.7 
End age, yrs 44 9.0+1-2.8 29 8.7+1-2.8 
Weeks in study 44 20+1-9.5 29 17+1-5.0 
Start FEY, % 46 98.4+1-15.8 (NIA) 
End FEY,% 27 98.1+1-17.4 (NIA) 
Target ht %ile group* 51 5.1+1-1.2 30 5.5+1- 1. 7 
Start ht %ile group* 51 3.3 +i-1.8 32 4.7+/-1.8b 
End ht %ile group* 39 3.0+1-1.7 27 4. 9+1-1.8b 
Start wt %ile group* 51 3.8+1-1.3 32 5.1 +l-1.6b 
End wt %ile group* 40 3. 7+1-1.3 27 5.2+1-1.6b 
Start wtlht %ile group* 44 4. 7+1-1.2 23 4.9+1-1.5 
End wt/ht %ile group* 32 4.9+1-0.9 16 4.8+1-1.4 
Start MAC %ile group** 51 7.6+1-4.6 31 13 .5+1-5.0b 
End MAC %ile group** 40 8.3+1-4.9 29 13 .0+1-4.8b 
Start AMC %ile group** 51 9.6+1-5.0 31 14.7+1-4.6b 
End AMC %ile group** 40 10.2+1-5. 1 29 14.8+1-4.0b 
Start AMA %ile group** 51 9.5+1-5.0 29 14.6+1-4.8b 
End AMA %ile group** 40 I 0.0+1-5.2 29 14.5+1-4.1 b 
Start TSF %ile group** 50 6.5+1-4.3 31 9.8+1-6 . 1 b 
End TSF %ile group** 40 7.1+1-4.6 29 9.5+1-6.1 
Start SS (mm) 46 5.8+1-2.2 31 7.5+1-3.7' 
End SS (mm) 40 7.8+1- 10.6 28 7.6+1-3.5 
* 1=<5%. 2=5-<10%, 3=10-<25%, 4=25-<50%, 5=50-<75%, 6=75-<90%, 7=90-<95%, 8=>1=95% 
** 1=<5%, 2=5-<10%, 3=10-< 15% .. 18=85-<90%, 19=90-<95%, 20=>1=95% 
'p<0.03 
'p<O.OI 
correlated with change in MAC percentile group (r=0.453, p=0.014), and change in 
weight percentile group positively correlated with change in AMA and AMC percentile 
groups (r=0.608, p=O.OOI and r=0.550 and p=0.003, respectively). None of the measures 
of change in arm fat and muscle stores correlated with change in spine BMD z score in 
either group. In the control group, change in TSF percentile group did correlate with 
change in distal arm BMD (r=0.466, p=O.Oll). 
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Initial Dietary Intake 
For a report on the initial 3-day diet intakes, see Chapter 2 Results (page 20). 
Daily Logs and Study Milk 
The mean length of participation in the study for the CF group was 20 weeks. 
The mean length of time that the daily logs were kept was 6.6 weeks (range of 0 to 17.7 
weeks). The daily vitamin consumption rate was 92% for this group. While the CF 
participants were instructed to drink three boxes of study milk/day during the study, the 
mean consumption was only 1.7 boxes of milk/day. ln addition to the study milk, they 
averaged 2.5 servings of high calcium foods/day. When the calcium contents of the study 
milk and high calcium foods were added together, the mean percent Dietary Reference 
Intake (DRl) of calcium from these sources during the study was 151% ( +/-70) for the CF 
group. 
The CF participants who received fortified milk were compared with the CF 
participants who received regular milk. The fortified milk group averaged 1.8 (SD 1.1) 
boxes of study milk per day, which was 917 mg calcium per day, while the regular milk 
group averaged 1.7 (SD 1.1) boxes per day, which was 442 mg calcium per day. The 
groups did not significantly differ in the number of additional servings of high calcium 
foods eaten per day (2.6 +/-1.2 in the fortified group versus 2.4 +1- 1.3 in the regular 
group). When the calcium contents for the study milk and high calcium foods were 
added together, the fortified group had a mean daily calcium intake of 1486 mg (SD 517) 
and the regular group's was 978 mg (SD 485). 
There were no significant differences between the fortified milk CF group and the 
Table 8 
Study milk groups 
CF fortified milk 
N Mean +I-S D 
Start age 29 8.5+/-2.9 
#of weeks in study 27 18.9+/-8.0 
#of weeks daily log kept 29 7.8+/-5.5 
Avg #of box milk/day' 18 1.8+/-1. 1 
Avg # srvgs high Ca foods/day ' 24 2.6+/- 1.2 
Avg mg Ca intake from box milk + high 17 1486+/-517 
Ca foods/day' 
%DRI for Ca from daily logs• 17 164+/-67 
%DRI for calcium from 3D DR 25 195+/-185 
S 25(0H) vitamin D' 20 34+/- 17 
S 1.25(0H)2 vitamin D• 18 47+/-25 
SPfH" 18 66+/-41 
Initial FEY ,% 25 97+/-17 
Final FEY,% 18 103+/-15 
Initial spine (L2-lA) z score 28 -0.018+/-0.558 
Change in L2-lA z score/wk 26 0.008+/-0.0 13 
Initial spine (L2-lA) BMD 28 0.585+/-0.116 
Change in spine (L2-lA) BMD/wk 26 9.92-4+/-1.39-3 
Initial distal radius+ulna BMD 28 0.218+1-0.046 
Change in distal r+u BMD/wk 24 9.63-5+/-2.21-3 
Initial proximal r+u BMD 28 0.448+/-0.1 03 
Change in proximal r+u BMD/wk 24 6.68-4+/-1.13-3 
'per daily Jog sheets 
'does not include total dietary intake 
' in ng/ml , normal reference range used= 12-60, CFF proposed minimum= 30 
'in pg/ml , normal reference range used= 18-62 
'in pg/ml, normal reference range used = 11 -54 
*p<O. IO 
**p<0.04 
N 
21 
17 
21 
9 
16 
9 
8 
17 
19 
19 
19 
20 
8 
21 
17 
2 1 
17 
2 1 
17 
21 
17 
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CF regular milk No milk/controls 
Mean +I-S D N Mean +I-SD 
9.0+1-2.6 32 8.3+/-2.7 
21.8+/-11.6 29 16.7+1-5. 1 
5.2+1-5.5 NIA 
1.7+/-1.1 NIA 
2.4+/-1.3 N!A 
978+/-485** N/A 
121+/-74 N/A 
165+/-171 26 94+/-30 
35+/-18 NIA 
36+/-31 N!A 
44+/-28** N/A 
99+/-15 NIA 
87+/-20* NIA 
0.031 +1-0.646 32 0.079+/-0.755 
0.013+/-0.027 29 0.009+/-0.008 
0.595+/-0.098 32 0.572+/-0. 112 
1.20-3+/- 1.53-3 29 2.80-3+/-2.04-3 * * 
0.2 16+/-0.045 32 0.208+/-0.050 
7.90-4+/-1.49-3 29 7.02-4+/- 1.35-3 
0.451+1-0.095 32 0.435+1-0.095 
(2.93-4+/-9.56-4 29 9.23-4+/- 1.22-3)* 
regular milk CF group in any measures of bone density or changes in bone density (Table 
8). However, there were a couple of differences found between the regular milk CF 
group and the control group that were not evident in the fortified milk CF group versus 
the control group. The regular milk CF group had less change in proximal arm BMD per 
week (p=0.073) as well as significantly lower final TSF percentile group values 
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(p=0.028). The fortified milk group had a mean serum PTH value that was above 
normal and higher than the regular milk group's (p=0.064), which was within the normal 
range. 
Table 9 
Daily logs (fortified and regular CF milk groups combined) 
N Mean SD 
# of weeks log was kept 51 6.6 5.6 
Servings high Ca foods/day" 40 2.5 1.2 
Boxes of study milk/dayb 27 1.7 1.1 
High Ca foods+ study milk (mg)/day 25 1323 553 
Missed or late enzymes/dayc 40 0.42 0.86 
Malabsorption symptoms/day" 40 1.1 1.1 
Daily vitamins taken• 40 0.92 0.13 
' I point each for 8 oz milk, I oz cheese, 5 oz yogurt; 1/2 point each for 4 oz pudding, 6 oz cottage cheese, 3/4 cup 
broccoli 
'a box of study milk is 8 oz 
' I point= no enzymes at meal , 112 point = no enzymes at snack, or enzymes taken after meal / snack instead of before 
eating 
' I point each for: more than 2 bowel movements/day, large amount of stool or diarrhea, stool floats in toilet, visible 
grease/oil with stool in toilet, gas/bloating 
" 'O"=vitamin not taken, "I "=vitamin taken 
The fortified milk group had significantly higher (p=0.037) final FEV 1% scores 
than the regular milk group. Other than FEV 1% scores, there were no significant 
differences between the regular and fortified milk CF groups, so they were combined to 
report daily log data (Table 9). Per the daily logs, the CF participants averaged 1.1 
malabsorption symptoms per day. The mean missed enzymes/day score was 0.42, with 
the following scoring system: one point for no enzymes at a meal, or one half point for no 
enzymes for a snack or if enzymes were taken after a meal or snack instead of before. 
The missed enzymes scores were highly correlated (r=0.529, p=O.OOl) with 
malabsorption symptoms. Missed enzymes were negatively correlated with the final 
AMC and AMA (r=-0.392, p=0.024 and r=-0.391, p=0.024, respectively) percentile 
groups, as well as the final FEY 1% score (r=-0.513, p=0.012). The change in FEY 1% 
score was negatively correlated with daily activity level (r=-0.582, p=0.004). 
Bone Measurements 
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Six CF participants and two controls had a history of previous fracture. None of 
these fractures were diagnosed as atraumatic, and none of these participants had spine 
BMD z scores less than or equal to --1.0. Table I 0 shows the group means for final and 
initial BMDs, BMCs, and spine areas. There were no significant differences between the 
means for the controls and CF group for any of these values. For a report on baseline 
bone measurements, see Chapter 2 Results. 
Within the CF group, the difference between males' and females' initial mean z 
score neared significance (p=.062), with females having a positive initial mean z score 
while males had a negative score (see Table 10). The difference between CF males' and 
females' final mean spine BMD z scores (females' mean z score was 0.5033, males' was 
-0.0594) was significant with a p value of 0.007. Jones and Dwyer12 found in their study 
of 330 8-year olds that females had higher size-adjusted BMD at the spine, while males 
had higher size-adjusted BMD at the hip. No significant differences were found between 
males' and females' BMD z scores in the control group, although the males' mean scores 
were slightly higher than the females '. 
Although there was no significant difference in either the initial or final BMD, 
BMC, spine area, or spine BMD z scores for the CF and control groups, there was a 
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Table 10 
Initial and final BMD (g/cm2) , BMC (g), spine area (cm2) and spine z score 
CF Controls* 
N Mean +I-SD N Mean +I-SD 
Start distal radius + ulna BMD 50 0.217+/-0.045 32 0.208+1-0.050 
End distal radius+ ulna BMD 41 0.226+1-0.056 29 0.227+/-0.046 
Start proximal radius+ ulna BMD 50 0.449+1-0.098 32 0.435+1-0.095 
End proximal radius+ ulna BMD 41 0.460+1-0.112 29 0.453+/-0. 1 09 
Start lumbar spine (L2-IA) BMD 50 0.588+/-0.1 07 32 0.572+/-0.0 II 
End lumbar spine (L2-IA) BMD 43 0.610+1-0. 121 29 0.597+/-0.126 
Start distal radius+ ulna BMC 50 0.583+1-0.186 32 0.567+/-0.021 
End distal radius+ ulna BMC 41 0.61 0+1-0.220 29 0.640+/-0.195 
Start proximal radius+ ulna BMC 50 0. 966+1-0.296 32 0. 942+1-0.029 
End proximal radius+ ulna BMC 41 0.982+/-0.314 29 1.001+/-0.322 
Start lumbar spine (L2-IA) BMC 50 16.62+/-6.07 32 17.15+1-7. 17 
End lumbar spine (L2-IA) BMC 43 17.29+/-6.69 29 18. 17+1-8.03 
Start spine area (L2-IA) 50 27.54+/-6.00 30 29.33+/-6.63 
End spine area (L2-IA) 43 27.60+/-5.83 29 29.55+1-6. 70 
Start lumbar spine (L2-IA) z score 50 -0.012+/-0.594 30 0.079+/-0. 755 
End lumbar spine (L2-IA) z score 43 0. 189+1-0.699 29 0.222+/-0.711 
Change in spine z score/wk 43 0.0096+1-0.0 196 29 0.0088+1-.0082 
*no significant differences between means of two groups 
difference in how they changed over the course of the study (Table 10). There was a 
significant difference in the change in spine BMD per week between the CF 
(mean=0.0028) and control (mean=O.OOll) groups (p=O.OOO). However, when looked at 
in terms of change in spine BMD z score per week, the CF group mean was slightly 
higher that the control group's mean, although not significant (p=0.827). When initial 
and final spine BMD z scores were compared within the groups, both the CF and control 
groups saw a significant increase over the period of the study (p=O.OOO)_ 
When the CF and control groups were split by gender and compared again, the 
difference between the CF and control males' mean change in spine BMD z score per 
week (0.0048 and 0.0116, respectively) neared significance (p=0.075), with the control 
males seeing a greater gain. When gender groups were compared within the CF and 
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control groups, the control males had a significantly higher increase (p=0.053) than the 
females (mean=0.0058). In the CF group, the difference neared significance (p=0.069) 
with the female group (mean=0.0157) having a greater increase in change in spine BMD 
z score per week than the males. Table 10 shows the group means for BMD, BMC, and 
spine area. There were no significant differences between the means for the controls and 
CF group for any of these values. 
Arm BMD values could not be converted to z scores for this data group. 
However, it is interesting to note than change in L2-IA BMD z score was positively 
correlated with change in distal radius plus ulna BMD in both the CF and control groups 
(r=0.424, p=0.06 and r=0.442, p=0.016, respectively), but not with change in proximal 
radius plus ulna BMD. Change in proximal and distal arm BMDs were not correlated 
with each other in either group. 
Because individuals had varying lengths of enrollment in the study, change in 
mean spine BMD z score was figured per week. There was no significant difference 
between the two groups in change in mean spine BMD z score per week. When the 
groups were split by gender however, there was a significant (p=0.044) difference 
between the CF and control females, with the CF females having a greater increase in 
mean z score. The control males had a slightly higher mean change in spine BMD z 
score than the CF males, but it was not significant. There were no significant differences 
between the groups in change in arm BMD per week. 
Regression analyses using the enter method were done for final spine BMD z 
score and change in spine BMD z score per week. However, even though the adjusted R 
square was high (0.455) for the final spine BMD z score model, the only significant 
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predictor was TSF percentile group (p=0.018). In the model with change in spine 
BMD z score per week as the dependent variable, the beta values were very low and no 
predictors were significant. A regression model may not be an appropriate assessment 
tool for this set of data because list-wise only 20 of the participants had all of the entered 
variables. 
Lab Values 
Serum and urine samples were obtained from 40 of the CF participants (see Table 
4). For a report on lab values and correlations with baseline data, see Chapter 2 Results. 
Serum 25(0H)D, the inactive form of vitamin D, was positively correlated with the final 
MAC (r=0.442, p=0.009), AMC (r=0.37l, p=0.031) and AMA (r=0.366, p=0.033) 
percentile groups. 
Serum vitamin A levels were positively correlated with change in proximal arm 
BMD per week (r=0.346, p=0.049) and negatively correlated with final MAC percentile 
group (r=-0.359, p=0.037), final TSF percentile group (r=-0.456, p=0.007), and final 
subscapular skinfold value (r=-0.343, p=0.047). No other lab values significantly 
correlated with change in spine BMD z score per week, change in distal arm BMD per 
week or change in proximal arm BMD per week. Serum vitamin E levels negatively 
correlated with final MAC (r=-0.440, p=0.009), AMC (r=-0.436, p=O.OIO), and AMA 
(r=-0.433, p=O.OIO) percentile groups. 
Compliance 
Several participants in the CF group were noncompliant in meeting and/or 
reporting all of the requirements for the study. Therefore, compliance was looked at as a 
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factor in itself. The CF group was broken down into compliant (n=l7), less compliant 
(n=8) and unknown groups (n=l6). The compliant group was simply defined as those 
who drank at least 75% of the boxed study milk and had both sets of bone scans 
completed. The less compliant group was defined as those who drank less than 75% of 
the boxed milk and had both sets of bone scans completed. The unknowns were those 
who failed to record or report how much of the milk they drank, but still completed the 
bone scans. The only significant difference found between these groups was for change 
in distal radius plus ulna BMD per week. The compliant and unknown groups both had 
significantly greater increases than the noncompliant group (p=0.002 and 0.012, 
respectively). The difference between the compliant and noncompliant groups in change 
in weight per week neared significance (p=0.085) with the compliant group gaining more 
weight. 
Discussion and Conclusions 
Demographics and Anthropometries 
The CF population used in this study had mild disease severity compared to 
national averages and groups used in comparative studies. The Cystic Fibrosis 
Foundation 1 (CFF) reported a range mean FEV 1% of approximately 95% to 80%, 
respectively, for children ages 6 up to 13.5 years. Our study included children ages 3 
through 13.5 years and their mean FEV,% predicted score was 98% (SD 16), which is 
considered normal, and is a relatively high value, even for a young CF group like this 
one. Unlike Henderson and Madsen13 and Haworth et al., 14 we did not find a relationship 
between BMD z scores and FEV 1%. Perhaps this was because most of our population 
had normal FEV I% scores and BMD z scores. Haslam et al. Is also did not find a 
relationship between FEV I% and BMD z scores in their children with CF. 
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The differences in how change in measures of arm muscle and fat correlated with 
each other and weight may reflect differences in how the groups gain weight. The fact 
that change in TSF percentile group negatively correlated with changes in AMA and 
AMC percentile groups may reflect the fact that when children with CF gain muscle, it is 
at the expense of fat tissue, or vice versa. Meanwhile, in the control group, change in 
TSF percentile group positively correlated with change in MAC percentile group, 
suggesting that gains in arm fat or muscle are additive, not replacing the other. Because 
adequate fat stores/nutrition are necessary for linear growth, this may be evidence of 
malnutrition associated with growth stunting in children with CF. 
The control group also saw a correlation between change in TSF percentile group 
and change in distal arm BMD, while the CF group did not. Perhaps weight gain (in 
terms of fat) influences arm bone density to a greater extent and/or more quickly than 
spine bone density. (The control group had a [nonsignificant] greater increase in weight 
percentile group than the CF group.) 
Changes in anthropometric percentile groups for age are difficult to interpret. 
This study was completed in less than a year for most participants. Meanwhile, age is 
used in increments of whole years to determine percentile groups. Therefore, the biggest 
determinant of change in percentile group may be whether a participant's birthday 
happened to fall within the study period, thus putting them in the next age group. 
Likewise, small increases in percentile group for age may be attributed to participants 
growing while still remaining in the same age group. 
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For example, a participant may go from recently turning 7 years old at the 
beginning of the study to being almost 8 years old at the end of the study. They grow 
during this time period, but still remain in the same age group. They go from being one 
of the youngest, and usually smaller individuals in this age group to being one of the 
oldest, and usually larger individuals in this age group. Therefore, their percentile group 
value may increase while their exact percentile for age may not. 
Another factor affecting change in percentile group is whether an individual was 
at the low or high end of their percentile group at the beginning of the study. Someone at 
the high end of their percentile group would be able to move up to the next percentile 
group much more easily than someone who started at the low end. 
Fortifed Milk Group vs. Regular Milk Group 
On average, CF participants drank only about half of the required amount of study 
milk, and kept the daily logs for only about one third of the required amount of time. 
This made it difficult to analyze and interpret the results. 
Even with the lack of compliance, the fortified and regular milk groups ended up 
consuming about the same amount of boxed milk and high calcium foods. Therefore, the 
difference in total calcium intake came from the fortification of milk. The fortified milk 
group ended up having double the calcium intake from boxed milk than the regular milk 
group did, and an average of approximately 50% more total calcium per day than the 
regular milk group. 
Another factor to take into consideration is that the "total" calcium intake from 
the boxed milk and high calcium foods consumed over the course of the study is not truly 
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a "total" calcium intake. Because participants did not keep a complete diet record, this 
"total" calcium intake is probably lower than actual calcium intake. The only foods 
recorded on the daily logs were specific high calcium foods. However, other foods eaten 
may still have had significant levels of calcium. For example, calcium fortified foods 
(like some orange juices, breakfast cereals, or snack foods), ice creams and sherbets, and 
cream soups or sauces could add significant amounts of calcium to the daily diet, not to 
mention other foods eaten that could contain lesser or trace amounts of calcium. "Total" 
calcium intake for the CF group over the course of the study was probably significantly 
underestimated. 
Having stated this, the CF group as a whole still had a significantly higher 
(p=0.014) mean calcium intake than the control group when their boxed milk and high 
calcium food calcium contents alone (mean daily "total" calcium intake between initial 
and final bone scans) were compared to the control group's mean daily calcium intake 
from the 3-day diet record at the beginning of the study. 
Although it probably would have been difficult to get this study group to comply, 
another 3-day diet record completed while drinking the study milk would have been 
informative. It could have shown if the study milk was being drunk in addition to the 
usual diet or in place of food items (specifically high versus low calcium foods) usually 
eaten. It was assumed that the controls' 3-day diet records would be representative of 
their typical intake throughout the study period. 
Although there were no significant differences between the fortified and regular 
milk CF groups in any measures of bone (Table 8), the fact that the CF regular milk 
group had significantly less change in proximal radius plus ulna BMD per week than the 
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control group did may be significant. Meanwhile, the CF fortified milk group did not 
differ significantly from the control group. In addition, although not significant, the 
fortified milk group had double the change in proximal radius plus ulna BMD per week 
than the regular milk group had (Table 8). So, while significant differences and changes 
in spine BMD and spine BMD z scores were hard to find, maybe the proximal bones of 
the arm better reflect short-term changes in calcium intake than does the spine. 
One factor that may have made differences between the fortified and regular milk 
groups difficult to find was initial serum PTH values (Table 8). The fortified group as a 
whole had much higher PTH values than the regular milk group. As noted in the 
previous section, the difference neared significance. Not only did the fortified milk 
group have higher values than the regular milk group, but their mean value was even 
above the normal range. Because serum samples were obtained at the start of the study, 
nothing done in the study could have influenced PTH values. Individuals were randomly 
assigned to milk groups, so it is interesting that there was such a difference between the 
groups with regards to PTH value. It is a factor that may have significantly impacted the 
results of the study, however. An elevated PTH value could be indicative of mild 
secondary hyperparathyroidism, which is a risk factor for osteopenia. In future studies, 
perhaps PTH values should be obtained prior to grouping individuals so that it can either 
be controlled for or used as a grouping variable. 
Daily Logs 
As expected, the missed enzyme score highly correlated with malabsorption 
symptoms. However, malabsorption symptoms did not correlate with any of the serum 
fat-soluble vitamin levels, or any of the serum/urine lab values, as might have been 
expected. They did not correlate with spine BMD z scores, either. It would have been 
interesting to have had z scores for BMD values of other bone sites, like the arm or hip, 
to see if malabsorption symptoms correlated with other types/sites of bone. 
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Although FEY 1% did not correlate with malabsorption symptoms, it did 
negatively correlate with missed enzymes. This means that the more enzymes missed, 
the lower the final FEY 1% score was. This may be of interest because while patients' 
observation and interpretation of malabsorption symptoms is a more subjective value, 
number of enzymes missed is an objective value. As may be expected, change in FEY 1% 
score and activity level were negatively correlated. In CF, FEY 1% scores generally are 
maintained in patients who are doing well , or decrease as patients age/decline in overall 
health. This means that as FEY 1% scores declined, so did activity level. Although 
causation cannot be concluded from correlation, it would make sense that decline in lung 
function would lead to decreased activity tolerance. 
It has often been hypothesized/stated that CF patients are less active than 
individuals without CF, and that this may be a factor in decreased bone density. 
Although the control group had a slightly higher mean activity level than the CF group, 
the difference was not significant. This agrees with the findings of Grey et al. 16 
Bone Measurements 
Our study was unique not only in that it used an intervention (study milk), but 
also because a second bone scan was done at least 3 months after the initial one. This 
allowed us to see how CF patients' bone measurements changed over time compared to 
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controls. We saw no significant difference s between the CF and control groups in how 
their spine bone density z scores changed over the course of the study. 
The only other longitudinal study found that was done on bone density in CF was 
the one published by Bhudhikanok et al. in 1998. 17 They did include some children in 
their study, but the youngest was nine years old, and they were combined as a group with 
youth up to age 18 (n=20) in the results. Bhudhikanok et al. 17 reported that their youth 
showed either static or decreasing BMD z scores (spine, hip, and whole body) over the 
1.5 year period of their study. 
In our study, spine BMD z scores significantly increased in both the control and 
CF groups. And, although the control group had significantly more improvement in 
change in spine BMD per week, there was virtually no difference between the groups 
when looked at in terms of change in spine BMD z score per week. Perhaps because z 
scores were determined categorically by age, it was more difficult to find significance in 
changes. For example, a participant who had a birthday while in the study could 
theoretically have the same change in bone density as another individual of the same 
initial age in years, but his/her z score may not reflect that change because their final z 
score would reflect the average of the next year of age group. 
Although not significant, both we and Bhudhikanok et al. 17 found greater 
improvement in the CFfemales' mean spine BMD z score than in the males'. In our 
study, the difference neared significance with a p value of 0.069. There were no 
differences in the CF group between the genders in changes in arm BMDs per week. In 
the control group, the males did have significantly higher improvement in change in 
distal arm BMD per week (0.00 12 versus 0.0002, p=0.045) than the females did. 
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It was notable that the CF females had significantly more improvement in spine 
BMD z scores than both the control females and the CF males. There were no significant 
differences between the genders in change in weight, height, or weight-for-height 
percentile groups. So while the gender differences in bone density cannot be attributed to 
differences in weight gained, there are likely other gender-specific variables that 
influence bone mineral accretion rates in various bone sites. 
Lab Values 
Other than vitamin A and change in proximal arm BMD per week, none of the lab 
values correlated with change in arm BMDs per week or change in spine BMD z score 
per week, as might be expected. There may be several reasons this relationship was not 
found. One might be that over the course of the study lab values improved if individuals 
took vitamins and enzymes more regularly/correctly than they did prior to the study 
because they had to report on it daily. Another possi bility might be that the follow-up 
bone scan was too soon to show effects of high or low Jab levels on bone formation. 
The fact that two of the fat-soluble vi tamins (A and E) were negatively correlated 
with final measures of arm muscle/mass may be noteworthy, particularly for nutrition 
monitoring. Those with low vitamin A and E levels may be at increased risk for 
nutritional wasting. Perhaps malabsorption is a factor in both low serum vitamin levels 
and less muscle/mass accumulation. 
Compliance 
Noncompliance on the part of participants was one of the biggest obstacles of this 
study. A large N value was an important objective to ensure that significance in results 
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would not be limited by a small study population. There could be several reasons for 
noncompliance in this population. One is that individuals with CF have highly 
regimented care. This includes treatments like daily home chest physical therapy, aerosol 
treatments, vitamin supplements, enzyme pills, high-calorie/protein diets, dietary 
supplements, regular check-ups, and hospital stays. In talking with care providers at the 
CF clinic as well as CF patients and their parents, we found that patients and their 
caregivers sometimes feel overwhelmed or discouraged by the demands of CF treatment. 
A main consideration in the development of this study was the rigorous care for 
individuals with CF, and trying to design a study with which they would be able to 
comply with. So, while the ideal may have been more detailed information, for example 
in dietary and activity records, or more information, like follow-up labs, these 
requirements probably would not have been practical or successful with this population. 
Perhaps in future studies where more funding is available, a pilot study should be done to 
identify and select compliant participants, who would then be randomly assigned to 
treatment groups. Greater incentive for compliance (like prizes or monetary 
compensation) may also help obtain a more detailed and complete data set. 
The fact that the compliant group in this study had a significantly greater increase 
in distal radius plus ulna BMD per week than the non-compliant group is noteworthy. 
The fact that these individuals were compliant with study requirements may indicate that 
they were also compliant with other aspects of their CF care. It would make sense that 
non-compliance itself may be a risk factor for osteopenia in CF. CF patients who do not 
correctly or regularly follow prescribed care like medications, vitamins, supplements, 
diets, therapies, check-ups, and routine hospital visits would be more likely to get 
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sick/infected more often (leading to deterioration of the lungs, lower activity levels, 
and/or declined overall health), and be malnourished, with consequent stunting of growth 
and delayed puberty. These are all likely risk factors for osteopenia. 
Notable Individual Results 
In terms of individuals in this study, there were some noteworthy results (Table 
11). Low bone mass is generally defined as a BMD between one and 2.5 SO below a 
mean value for a given population. Goulding et al. 18 reported from their findings that 
each SD decline below the mean total body BMD for youth doubles the risk of fracture. 
In our study, there were two children in both the CF and control groups than had BMD z 
scores less than -1.0. 
The control group had the two lowest BMD z scores (see Table 11). Both of them 
were 6-year old females with low height and weight. One of them did not complete a 3-
day diet record or anthropometric measurements, but the other showed low dietary intake 
levels of calcium (61% DRI) and energy (66% RDA), and very low fat stores per TSF 
measurement (less than the 5th percentile). 
Both of the CF subjects with low spine bone density were males. One was 3 
years old, the other 8. Both exceeded calcium intake levels, but the 3-year old exceeded 
CF recommendations for caloric needs while the 8-year old fell short. The 3-year old had 
close to average height and weight while the 8-year old was below 5th percentile on 
height for age and below the 25th percentile on weight for age. 
Labs varied between these two subjects. The only noteworthy labs on the 3-year 
old subject were low PTH and 25(0H)D levels (per CFF proposed recommendations). 
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Table 11 
Initial and final characteristics of individuals with low bone density 
CF 
M, a e 3 M, aoe 8 Mean 
10# 34 20 73 83 
Start L2-LA BMD z score -1 .07 -1.10 -0.01 - 1.17 - 1.43 0.08 
End L2-LA BMD z score -1.10 -1.12 0.19 N/A -1.18 0.22 
Change in L2-LA BMD z score/wk -0.0022 -0.0017 0.0097 N/A 0.0163 0.0088 
Target ht %ile group* 6 4 5.1 5 6 5.5 
Start hto/oile group* 5 3.3 2 4 4.7 
End ht %ile group* 5 I 3.0 N/A 4 4.9 
Start wt %ile group* 4 3 3.8 2 3 5.1 
End wt %ile group* 5 2 3.7 N/A 3 5.2 
W tlht %ile group* 4 4 4.7 4 2 4.9 
Start AMC o/oile group** 8 3 9.6 NIA 12 14.7 
End AMC %ile group** 10 3 10.2 N/A 9 14.8 
Start AMA %ile group** 8 3 9.5 N/A 12 14.6 
End AMA %ile group* * 10 3 10.0 N/A 9 14.5 
Start TSF %ile group* * 4 8 6.5 NIA 9.8 
End TSF %ile group** 4 13 7.1 NIA 9.5 
FEY, % (too young) 112 98.4 N/A N/A N/A 
S I ,25(0H), vitamin D' 54 10 41.1 NIA NIA NIA 
S 25(0H) vitamin D' 20.5 25 .0 33.6 N/A N/A N/A 
S PfH' 10 62 53.8 NIA NIA NIA 
S vitamin A' 56 39.5 51 NIA NIA NIA 
S vitamin E' 16.5 12.4 14.1 N/A N/A N/A 
S at kat i ne phosphatase' 93.5 28.4 64.6 N/A N/A N/A 
%RDA for Calories 117 150 105 N/A 66 60 
%DRI for calcium 238 274 183 N/A 61 94 
Avg It enzyme doses missed/d 0 2.0 0.4 NIA NIA N/A 
Avg #malabsorption symptoms/d 0.6 2.3 l.l NIA NIA NIA 
Avg activity level (on scale 0-5) 2.5 2.7 2.8 N/A 2.0 3.1 
*1=<5%, 2=5-< 10%, 3= 10-<25%, 4=25-<50%, 5=50-<75%, 6=75-<90%, 7=90-<95%, 8=>1=95% 
** 1=<5%, 2=5-<10%, 3= 10-< 15% . . 18=85-<90%, 19=90-<95%, 20=>1=95% 
"in pg/ml , normal reference ran ge used = 18-62 
bin ng/ml , normal reference range used = 12-60, CFF proposed minimum = 30 
"in pg/ml, normal reference range used= 11 -54 
din mg/ml , normal reference range used= 30-100 for ages l -5y , 60- 100 for ages 5-16y 
'in mmol/1 , normal reference range used= 10-21 for ages l-6y, 13-24 for >6y 
rin IU/L, normal reference range used= 47-112 
Typically, one would expect to see elevated PfH if vitamin D levels were low. The 8-
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year old had several abnormal lab values, including low 1,25(0H)2D, 25(0H)D (per 
CFF proposed recommendations), vitamin A, vitamin E, and alkaline phosphatase. PTH 
was elevated. These labs could indicate malabsorption and consequent mild secondary 
hyperparathyroidism, which could be contributing to decreased bone density. He had 
good lung function, as evidenced by a high FEY 1% score (112% ). 
Both of the CF subjects completed the study, but only one of the two controls did. 
Both of the CF subjects had a slightly negative change in spine BMD z score per week 
while the control had a slightly positive change (see Table 11). There were also 
differences in how their anthropometries changed. The 8-year old CF male stayed in the 
same AMC and AMA percentile groups (group three for both) over the course of the 
study, but went from percentile group eight to 13 for TSF. He was catching up in fat 
stores, but remained malnourished in terms of muscle stores. The 3-year old CF male 
increased in both AMC and AMA percentile groups (from eight to 10 for both), but TSF 
percentile group stayed the same (group four). The 6-year old control female went down 
in both AMC and AMA percentile groups (from 12 to nine for both), but remained in 
group one for TSF percentile (less than the 5th percentile for age). 
Both CF children surpassed the RDA for caloric intake and more than doubled the 
DRI for calcium intake (Table 11). On average, the 3-year old CF male missed less than 
one half an enzyme dose each day and had Jess than one malabsorption symptom per day . 
On average, the 8-year old CF male missed two enzyme doses each day and had over two 
malabsorption symptoms per day. This evidence would support the above-mentioned 
theory that this child had significant malabsorption, contributing to low serum fat-soluble 
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vitamin levels, including vitamin D, leading to secondary hyperparathyroidism and 
consequent bone deficits. 
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Our results were in full accordance with one of our three hypotheses. The 
hypotheses of this study were: (1) children with Cystic Fibrosis (CF) are smaller than 
healthy children without CF; (2) children with CF have less dense bones than healthy 
children without CF; (3) calcium intake is correlated with bone density in both children 
with CF and healthy children without CF. Children in this CF study population are 
smaller than healthy children without CF in the same population. It could not be proved 
that children with CF have less dense bones than healthy children without CF. Calcium 
intake was not correlated with bone density in children with CF, but there was a 
correlation in the healthy control children. 
No major differences were found in how children with CF and healthy controls 
gain bone mass. The results of these two studies concur with at least four other published 
studies, 1•23 .4 as discussed in the individual papers, and provide further evidence for normal 
bone density in children with CF. However, the fact that there are at least two other 
published studies5·6 that have shown decreased bone density in youth with CF requires 
addressing. 
Each of these studies was done on a different CF population, except for the 
Mortensen et al.2 study, which drew its participants from the same population (same 
geographical area and clinic) as this study and also found no bone deficiencies in CF 
youth. So, perhaps CF populations in different geographical areas differ in mean bone 
density. Factors such as continuity and quaJity of care at individual CF centers could be a 
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contributing factor to overall health of individuals. Where a CF population is 
geographically located may affect the amount of sunshine exposure patients receive in a 
given year, thus affecting vitamin D levels. 
If deficits are due to a CF-related primary defect in bone mineral metabolism, 
they may only be evident in more severe disease/as disease progresses. Our CF 
population was young and had mild disease per percent predicted forced expiratory 
volume in 1 second (FEY 1% ). Perhaps multi-center research involving larger child 
populations with varying degrees of disease severity would help to define if and what the 
role of disease severity is in the development of osteopenia. 
Another important point is that our CF group was well-nourished and had mild 
disease relative to national CF averages and other studies. If the etiology of osteoporosis 
in CF is related to either of these factors, our population may be more protected than 
other groups studied. Perhaps deficits seen in other studies were related to more severe 
malnourishment or more advanced disease/poorer health and related factors (such as 
activity). Then, the question would be "Why does this population have relatively mild 
disease and better nutritional status?" These would be issues to address in future 
research. 
The age of a study population could also significantly impact results. The range 
and mean of ages in a study group would impact mean bone density for a group of 
"children," "youth," "adolescents," or "pre-pubescents" in each of these studies. The 
size of the study group is also important in determining if results/differences are 
significant. As mentioned in the individual papers, some of the studies referenced had 
small study groups. Ours was the largest pre-pubescent study group of those found on 
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bone density in CF. Our group was also younger overall than other study groups, 
which could have several implications. One may be that delayed puberty and insufficient 
catch-up are important in the etiology of osteopenia. Our study group was young enough 
that these factors should not have had an impact yet. Additional studies on separate pre-
pubescent, pubescent, and post-pubescent groups would help to confirm if this were the 
case. 
Another important factor in all studies done on bone density, and perhaps one of 
the greatest sources of variance between studies, is type of bone measurement- both 
bone site and equipment/technique used. There is no generally accepted standard at this 
time to allow direct comparison in study results. While dual energy x-ray absorptiometry 
(DEXA) is currently considered the "gold standard" by many in the field due to 
precision, accessibility, low radiation, and lower cost, computer tomography (CT) gives 
much more information, but at the cost of higher radiation exposure , less accessibility, 
and higher price. Until the field of bone density research agrees upon a standard, both in 
bone site measured and equipment/technique used, the puzzle of osteoporosis in CF may 
be a difficult one to solve. 
There is need for better reference data and diagnostic criteria for bone disease in 
children. Until there is, it will be difficult to standardize and compare results within and 
between studies. Not only is more adequate data needed for bone density in children in 
general, but also in relation to body size and pubertal stage to make results more 
meaningful. 
New markers of bone metabolism are being researched and discovered 
continually. As new tests become available that are more precise, affordable and 
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accessible, researchers will be able to better pinpoint which metabolic markers may 
indicate risk for net bone deficits. In our study, parathyroid hormone (PTH) was an 
interesting variable in relation to bone density and vitamin D levels. The results of our 
study would merit additional research on the relationship between PTH and bone density 
in CF. In the meantime, more focus should be placed on bone density within CF clinics 
by implementing screening tools, like monitoring serum PTH, vitamin D and alkaline 
phosphatase levels to identify those children who may be at risk for developing 
osteopenia. Then, additional precautions can be taken, like increased vitamin D/calcium 
supplementation or bone scans, or even just monitoring at-risk individuals more 
frequently . 
Malabsorption is an ever-present problem in CF. Our study group was no 
exception, as evidenced by abnormal lab values, malabsorption symptoms, and 
suboptimal enzyme usage. These indicators all point to risk for nutrient deficiencies 
which could increase risk for osteopenia in the future. Future longitudinal studies need to 
address and study the issue of malabsorption and bone density in CF more closely. 
Osteoporosis in CF is a very complicated issue to research. CF and osteoporosis 
are very complex diseases independently, and to try and find individual relationships 
when looking at them together is very difficult. It is probably safe to assume that 
osteoporosis in CF is most likely multifactorial. The fact that the substantial amount of 
research that has been done points in so many directions, rather than at just one or two 
factors, would attest to this. The two individuals in this CF group with low bone density 
may also be evidence of this. Compared to each other, they had very different profiles. 
There may be various risk factors for osteopenia in CF present to different extents in 
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different individuals, and when external/environmental factors figure in also, 
individual variance in risk could be very high. 
Although additional calcium and vitamin D did not significantly increase bone 
density in this study, they can not be ruled out as treatment options by any means. It may 
just be that levels were not right, or that the time period in which they were administered 
were not long enough to see results. Or, perhaps the high levels of calcium that this CF 
group was already consuming was at a level for maximum benefit in terms of bone 
building. Perhaps in individuals with CF who are consuming sub-optimal levels of 
calcium this type of fortification may be a very inexpensive and convenient way to help 
reduce risk for osteopenia. The additional calories, fat, protein, vitamin D, and other 
nutrients contained in the milk product would be of nutritional benefit, as well. 
Additional intervention studies further examining calcium and vitamjn D, as well as other 
osteoporosis treatment options (like those used in post-menopausal women), in CF 
populations that have or are at risk for osteoporosis would be informative and beneficial 
in developing preventative and treatment options. 
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APPENDIX A 
INVITATION FOR CHILDREN WITH CFTO PARTICIPATE IN STUDY 
INTERMOUNTAIN CYSTIC FIBROSIS CENTER 
Department of Pediatrics 
Primary Children 's Medical Center 
I 00 North Medical Drive, Salt Lake City, Utah 84113 
Research Study Opportunity 
Dear Parent(s): 
We invite your child to participate in a research study on bone mineralization in children with cystic 
fibrosis (CF). This study is being conducted by Primary Children 's Medical Center, the Intermountain 
Cystic Fibrosis Center, and Utah State University. There will be no additional cost to you for 
participation. The care your child receives at Primary Children's Medical Center or the Intermountain 
CF Center will not be affected by whether you decide to have your child participate or not participate in 
this study. 
Purpose: 
The purposes of this study are to evaluate the differences in bone mineralization between children with 
CF and children without CF, and the effect of a specially fortified milk on bone mineralization. It is 
estimated that up to 20-50% of children with CF may have undermineralized or weak bones. Improving 
bone mineralization will promote better health. 
Qualifications: 
Your child must have Cf, be between the ages of3 and 16 years, and not reached puberty. 
Requirements: 
Your child will be asked to: 
1) Drink three 8 ounce servings of either regular milk or fortified milk each day for at least three months. 
The milk will be provided for your child. 
2) Have blood drawn at the beginning of the study. We will try to coordinate these blood draws with the 
routine or annual lab work done in CF clinic. 
3) Give a urine sample. 
4) Have a bone scan done (similar to an X-ray). Your child will need to lie still for about 10 minutes. 
5) Keep a 3-day diet record at the beginning of the study. 
6) Keep a simple daily log of enzyme use, activity level, malabsorption symptoms and dietary calcium 
intake. (Estimated time to complete this log will be less than 5 minutes per day.) 
Benefits: 
1) Assessment of bone mineralization (early detection if there are problems) 
2) Three servings of milk per day for at least three months at no cost 
3) Increased skills in monitoring signs and symptoms of malabsorption 
4) Possibly stronger bones 
5) Possibly improved nutritional status 
We are enclosing a response card and postage-paid self-addressed envelope. If we do not hear back from 
you in the next week, we may call you to obtain your preference. We look forward to hearing from you. 
Sincerely, 
·~)d~ 
Katie McDonald, RD 
Dietitian, CF Outpatient PCMC 
(801) 588-3898 
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APPENDIX B 
LEITER INSERT FOR RECRUITMENT OF HEALTHY CONTROLS 
P.S. We are also looking for healthy children without CF to participate in this study. To be eligible, 
they must be between the ages of 3 and 16 and not have reached puberty yet. They will not 
need to drink any special milk or certain amount of milk -- they will consume their usual diet. 
They will not need to give a blood or urine sample or keep a daily log. They will be asked for the 
following: 
1) a bone scan (like an x-ray) at the beginning of the study 
2) anthropometric measurements (height. weight. etc.) at the beginning and 
end of the study (which will last 3-4 months) 
3) a 3-day diet record at the beginning of the study 
If you would be interested in having any of your children without CF involved in this study (you 
may have more than one child enrolled in the study - with or without CF), please write their 
name(s), sex and age below along with a phone number and return it with the enclosed response 
card in the provided envelope. 
Name _______ _ Sex: F M Birthdate:, ____ _ 
F M 
Phone#: ( 
( 
If you have any relatives, friends, or neighbors that may be interested in participating, please have 
them call Katie McDonald at (8"01) Sl5/3-3ggg or e-mail Joanna Kelley at sly7b@cc.U$!Ledu. 
P.S. We are also looking for healthy children without CF to participate in this study. To be eligible, 
they must be between the ages of 3 and 16 and not have reached puberty yet. They will not 
need to drink any special milk or certain amount of milk -- they will consume their usual diet. 
They will not need to give a blood or urine sample or keep a daily log. They will be asked for the 
following: 
1) a bone scan (like an x-ray) at the beginning of the study 
2) anthropometric measurements (height, weight, etc.) at the beginning and 
end of the study (which will last 3-4 months) 
3) a 3-day diet record at the beginning of the study 
If you would be interested in having any of your children without CF involved in this study (you 
may have more than one child enrolled in the study - with or without CF), please write their 
name(s), sex and age below along with a phone number and return it with the enclosed response 
card in the provided envelope. 
Name _______ _ Sex: F M Birthdate: ____ _ 
F M 
Phone#: ( 
( 
If you have any relatives, friends, or neighbors that may be interested in participating, please have 
them call Katie McDonald at (gol) sgg-3ggg or e-mail Joanna Kelley at sly7b@cc.U$!Ledu. 
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RESPONSE CARD 
Please return this card within the next few days to let us know if you are interested in participating in this study. 
0 Thank you, but we are not interested in participating at this time. 
0 Yes, we are interested in participating. Please send us additional information about the study. 
Child's Name: 
Parent's Name: 
Phone # to be reached at: Day: Evening: 
If we do not receive this in the next week, we may call you to obtain your preference. Thank you for your time! 
RESPONSE CARD 
Please return this card within the next few days to let us know if you are interested in participating in this study. 
0 Thank you, but we are not interested in participating at this time. 
0 Yes, we are interested in participating. Please send us additional information about the study. 
Child 's Name: 
Parent 's Name: 
Phone # to be reached at: Day: Evening: 
lfwe do not receive this in the next week, we may call you to obtain your preference. Thank you for your time! 
RESPONSE CARD 
Please return this card within the next few days to let us know if you are interested in participating in this study. 
0 Thank you, but we are not interested in participating at this time. 
0 Yes, we are interested in participating. Please send us additional information about the study. 
Child's Name: 
Parent ' s Name: 
Phone # to be reached at: Day: Evening: 
If we do not receive this in the next week, we may call you to obtain your preference. Thank you for your time! 
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INFORMED CONSENT FOR THE CHILD WITH CF 
H PRIMARY CHILDREN'S MEDICAL CENTER 
I H C A Service of ln termounlQin Health Care 
Informed consent for the 
child with cystic fibrosis 
Page 1 of 4 
I 00 North Medica l Drive 
Salt Lake City, Utah 84 11 3 
(80 1) 588-2000 
(801) 588-2460 F" 
The Effect of Fortified Milk on Bone in Cystic Fibrosis 
We invite your child to take part in a research study at Primary Children's Medical 
Center and the Intermountain Cystic Fibrosis Center. It is important that you read and 
understand several general principles that apply to all who take part in our studies: 
(a) taking part in the study is entirely voluntary; 
(b) personal benefit may not result from taking part in the study, but knowledge may be 
gained that will benefit others; 
(c) you may withdraw your child from the study at any time without penalty or loss of 
any benefits to which your child is otherwise entitled. 
The nature of this study, risks, inconveniences, discomforts, and other pertinent 
information about the study are discussed below. You are urged to discuss any questions you 
have about this study with the staff members who explain it to you. 
Purposes: 
The purposes of this study are: 
1) to evaluate the differences in bone mineralization between children with cystic fibrosis 
(CF) and healthy children without cystic fibrosis. 
2) to determine the physiology (or body's use) of calcium and vitamin Din children with 
CF. 
3) to evaluate the effects of calcium supplementation using specially fortified dairy 
products on bone mineralization in children with CF. 
Basis for selection 
We are asking that your child participate in this study because she/he is between the ages 
of2 and 16 years and has not reached puberty. Children with CF and healthy children without 
CF will be asked to participate in this study. 
Explanation of procedure for the child with CF 
If you decide to participate in this study, your child will be asked to consume at least 
three 8 ounce servings of either regular milk or the fortified milk each day for a period of three 
months. Which dairy product (either regular milk or a fortified calcium and vitamin D milk) 
your child will use for a three month period will be decided based on chance. All children will 
continue to eat their regular diet in all other respects and receive their usual medical treatments. 
All CF children will continue on their prescribed pancreatic enzymes, medications and vitamin 
and mineral supplements during the study period. 
A mutually agreeable time will be arranged for study participants to come in for the pre-
study data collection. The study participants will return at three months for the post-study data 
collection. Both the pre-study and post-study data collections can be timed to occur on the 
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M PRIMARY CHILDREN'S MEDICAL CENTER 
IHC A Service. of lmermounlain Heolrh Ca re 
Page 2 of4 
I 00 North Medical Drhe 
Salt Lake City, Utah 84 11 3 
(801) 588-2000 
(80 I) 588-2460 Fax 
same days as regularly scheduled, quarterly CF Outpatient Clinic appointments at Primary 
Children's Medical Center. The pre- and post- study data collections for children with CF will 
include: 
I. Weight, height, chest circumference, arm circumference and skinfold measurements. 
2. Bone mineral analyses by DEXA (Dual energy X"ray absorptiometry, similar to an X-
ray) of the lower spine and/or forearm will be completed at Dr. Gary Chan's lab at the 
University of Utah Medical Center. 
3. A 5 ml (1 teaspoon) blood sample taken from a vein.* 
4. An early morning urine sample.* 
*Note: Any abnormal value in the blood or urine sample will be reported immediately to your 
doctor who will arrange appropriate medical follow up. 
The CF child or a parent will complete and mail in a three day diet record at the 
beginning of the study. For the remainder of the three months study, the child and/or parent 
will keep simple daily logs to report changes in bowel movement, the amount of calcium in your 
child's diet, pancreatic enzyme usage, level of activity and vitamin mineral supplement usage. 
The child and/or parent will be instructed on using the diet records and the log. The logs will be 
submitted weekly. Prepaid, self addressed envelopes will be provided. 
Procedures that are not part of routine CF care: 
By agreeing to participate in this study, you should realize that the bone mineral analyses, 
the blood draws, urine collections and the daily logs are not part of ordinary CF care. 
The bone mineral analyses take about five minutes and require walking from PCMC 
Outpatient CF clinic to the Dr. Chan's Lab at the University of Utah Medical Center 
(approximately 10 minutes each way). 
In order to minimize the number of blood draws, entry into the study can be scheduled 
to coincide with armual or scheduled blood work. 
The daily log will be completed every day for three months. It is estimated that the time 
to complete the log should be less than five minutes per day. 
Listing of costs resulting from the research: 
The costs of this research are being paid for by a grant from the Primary Children's 
Medical Center Foundation. The fortified milk was developed at Utah State University and 
donated by the Utah Dairy Commission. All investigators are donating their time to conduct this 
research. There is no cost above the usual for routine CF care to the study subjects or their 
parents. 
Potential benefits 
The potential benefits of this study include early identification of any bone 
demineralization, a procedure that is not currently a part of routine care for children with CF. 
Increased skill in monitoring signs and symptoms of poor intestinal absorption may result in 
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improved control and better weight gain. It is possible that the use of the fortified dairy product 
may increase bone strength. 
Description of risks and disco!l"forts: 
Any treatment has potential side effects. It is expected there should be minimal side 
effects from the substitution of fortified milk for regular milk in the diet of a child with CF. 
Lactose intolerance is a potential side effect for the child who does not normally consume milk. 
Gastrointestinal symptoms such as diarrhea, gas or possibly constipation could occur. 
A small discomfort may be felt for less than five seconds with the compression of 
skinfolds or "pinch" in determining skinfold measurements. Children who attend the Outpatient 
CF clinic at PCMC have these measurements done as a routine part of care. 
Although the risks of having blood taken from a vein are minimal, there may be a small 
amount of pain when the needle is inserted into the vein and there may be some residual bruising 
in the days after the blood is drawn. 
A small radiation exposure occurs with the use of the DEXA bone analysis. This 
exposure is estimated to be approximately 40 times less than the radiation exposure of a chest or 
dental X-ray. 
Disclosure of alternatives: 
The alternative to this study is to decline enrollment. You should feel free to discuss with 
your child's doctor the possibility of increasing the amount of calcium your child consumes 
before you decide whether to participate in this study. 
Voluntary Participation: 
Participation in this study is entirely voluntary and you may choose to decline to have 
your child enrolled in this study. If you do participate, you can withdraw your child at any time 
without any effect on his/her medical care. 
Questions? 
If you have any questions about this study, they will be answered by Katie McDonald or 
Dee Anne Evans. You can contact Katie at (801) 588-3898 and Dee Anne at (801) 588-2716 or 
through the operator at Primary Children's Medical Center at (801) 588-2000. If you have any 
questions concerning your child's rights as a research subject, you may contact David P. Carlton, 
MD, Chairman of the Research and Human Subjects Committee at Primary Children's Medical 
Center at (801)581-4186. 
In case of injury: 
Realistically, neither Primary Children's Medical Center, the Intermountain Cystic 
Fibrosis Center, Utah State University nor the investigators can guarantee or assure that unknown 
consequences will not occur. If you believe that your child has suffered an injury as a result of 
participation in this research program, please contact Primary Children's Medical Center Risk 
Manager, Susan W. Adams, RN, BSN at (80 1 )588-2281 . You will not give up any of your 
child's legal rights by signing this form. 
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Upon consideration of the possible benefits and risks of this study outlined, I voluntarily 
agree to allow the participation of in the study. 
I understand that effective medical care is my doctors' and the investigators' main 
concern and that they may stop the study and change my child's treatment according to their best 
judgement. My questions regarding participation in this study have been answered and I 
understand the explanation. 
Confidentiality assurance: 
I give permission for the information gathered in this study and pertinent information 
from my child's medical records to be released to the investigators with the understanding that 
they may be published for scientific purposes, but my child's identity will not be publicly 
revealed without my written consent. By federal law, the medical information gathered in the 
course of this study may be reviewed by the United States Food and Drug Administration. I 
acknowledge receipt of a copy of this consent document. 
Signature of Patient (if applicable) 
Signature of Parent/ Guardian 
Signature of Witness 
--/(a:/iv ./1-t!{)f;~f I~ 
Katie McDonald, MS, RD 
Clinical Dietitian 
Intermountain Cystic Fibrosis Center 
Primary Children's Medical Center 
I have reviewed for "typos" and spelling and grammatical errors. 
Date 
Date 
Date 
If any of the above items are not included, describe basis for exclusion: 
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The Effect of Fortified Milk on Bone in Cystic Fibrosis 
We invite your child to take part in a research study at Primary Children's Medical 
Center and the Intermountain Cystic Fibrosis Center. It is important that you read and 
understand several general principles that apply to all who take part in our studies: 
(a) taking part in the study is entirely voluntary; 
(b) personal benefit may not result from taking part in the study, but knowledge may be 
gained that will benefit others; 
(c) you may withdraw your child from the study at any time without penalty or loss of 
any benefits to which your child is otherwise entitled. 
The nature of this study, risks, inconveniences, discomforts, and other pertinent 
information about the study are discussed below. You are urged to discuss any questions you 
have about this study with the staff members who explain it to you. 
Purposes: 
The purposes of this study are: 
I) to evaluate the differences in bone mineralization between children with cystic fibrosis 
(CF) and healthy children without cystic fibrosis . 
2) to determine the physiology (or body 's use) of calcium and vitamin Din children with 
CF. 
3) to evaluate the effects of calcium supplementation using specially fortified dairy 
products on bone mineralization in children with CF. 
Basis for selection 
We are asking that your child participate in this study because she/he is between the ages 
of 2 and 16 years and has not reached puberty. Children with CF and healthy children without 
CF will be asked to participate in this study. 
An explanation of procedure for the child without CF: 
If you decide to participate in this study and your child does not have CF, your child will 
continue to eat his or her usual diet and continue his or her usual consumption of milk for the 
three month study period. A mutually agreeable time will be arranged for study participants to 
come in for the pre-study data collection. The study participants will return at three months for 
the post-study data collection. 
Data collection for the child without CF will be the following : 
I. Pre- and post-study weight, height, chest circumference, arm circumference and 
skinfold measurements. 
2. A bone mineral analysis by DEXA (Dual energy X-ray absorptiometry, similar to an 
X-ray) of the lower spine and/or forearm will be completed at Dr. Gary Chan's lab 
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3. A three day diet record will be completed and mailed in. The child and/or parent will 
be instructed on using the diet records. Prepaid, self addressed envelopes will be 
provided. 
Listing of costs resulting from the research: 
The costs of this research are being paid for by a grant from the Primary Children's 
Medical Center Foundation. All investigators are donating their time to conduct this research. 
There is no cost to the study subjects or their parents. 
Potential benefits 
The potential benefits of this study include early identification of any bone 
deminenilization, a procedure that is not currently a part of routine care for children. 
Description of risks and discomforts: 
A small discomfort may be felt for less than five seconds with the compression of 
skinfolds or "pinch" in determining skinfold measurements. 
A small radiation exposure occurs with the use of the DEXA bone analysis. This 
exposure is estimated to be approximately 40 times less than the radiation exposure of a chest or 
dental X-ray. 
Disclosure of alternatives: 
The alternative to this study is to decline enrollment. 
Voluntary Participation: 
Participation in this study is entirely voluntary and you may choose to decline to have 
your child enrolled in this study. If you do participate, you can withdraw your child at any time 
without any effect on his/her medical care. 
Questions? 
If you have any questions about this study, they will be answered by Katie McDonald or 
Dee Anne Evans. You can contact Katie at (801) 588-3898 and Dee Anne at (801) 588-2716 or 
through the operator at Primary Children's Medical Center at (801) 588-2000. If you have any 
questions concerning your child's rights as a research subject, you may contact David P. Carlton, 
MD, Chairman ofthe Research and Human Subjects Committee at Primary Children's Medical 
Center at (801)581-4186. 
In case of injury: 
Realistically, neither Primary Children's Medical Center, the Intermountain Cystic 
Fibrosis Center, Utah State University nor the investigators can guarantee or assure that unknown 
consequences will not occur. If you believe that your child has suffered an injury as a result of 
participation in this research program, please contact Primary Children's Medical Center Risk 
Manager, Susan W. Adams, RN, BSN at (801)588-2281. You will not give up any of your 
child's legal rights by signing this form. 
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Upon consideration of the possible benefits and risks of this study outlined, I voluntarily 
agree to allow the participation of in the study. 
I understand that effective medical care is my doctors ' and the investigators' main 
concern and that they may stop the study and change my child's treatment according to their best 
judgement. My questions regarding participation in this study have been answered and I 
understand the explanation. 
Confidentiality assurance: 
I give permission for the information gathered in this study and pertinent information 
from my child's medical records to be released to the investigators with the understanding that 
they may be published for scientific purposes, but my child's identity will not be publicly 
revealed without my written consent. By federal law, the medical information gathered in the 
course of this study may be reviewed by the United States Food and Drug Administration. I 
acknowledge receipt of a copy of this consent document. 
Signature of Patient (if applicable) 
Signature of Parent/ Guardian 
Signature of Witness 
')\CL f;_e ~t/VL cfil~f}l t/J 
Katie McDonald, MS, RD 
Clinical Dietitian 
Intennountain Cystic Fibrosis Center 
Primary Children's Medical Center 
I have reviewed for "typos" and spelling and grammatical errors. 
Date 
Date 
Date 
If any of the above items are not included, describe basis for exclusion: 
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The Effect of Fortified Milk on Bone in Cystic Fibrosis 
Youth Assent: 
________ explained this research project to me. I understand what will happen 
during this research. I have asked the questions I want to ask and my questions have been 
answered. I understand that my parent(s) has/have given their permission for me to participate in 
this study. My signature below indicates that I am willing to participate. I know that I do not 
have to do this. I know I can stop being in this study at any time by telling my parents, Katie 
McDonald (the CF clinic dietitian), or Dee Anne Evans (the CF nurse practioner) that I do not 
want to be in this research project. 
Signature of child Age of child Date 
This statement has been read to the above child and he or she seems to understand. 
Signature of person obtaining assent 
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APPENDIX G 
DATA SHEET FOR CHILD WITH CF 
CF Bone Mineralization Study Data Sheet 
Date 
Name 
Group 
ID# 
Age 
Sex 
INITIAL FINAL 
Anthropometry Date: ___ _ Date: ___ _ 
Height 
Weight 
BMI 
MAC 
AMC 
Arm Area 
AMA 
Triceps 
Subscapular 
Chest Circumf. 
CF Severity (Schwachman-Kulcyzycki): 
Consent Form 
_ Explained/Qstns Answered 
Signed? Y I N Date: ___ _ 
Starter Packet Given & Explained 
_ 3-Day Diet Record 
Portion Sizes 
_Daily Log (see reverse side) 
_ SASE's/Weekly Mail-In 
Dad's HI 
Mom's HI 
Kyphosis? (per x-ray) YIN 
Previous Fractures? Y I N 
How Many? 
Location(s): ___ _ 
Cause: 
Date 3-Day Record Returned: 
_ Gassner UHT Milk Info (Remind to SHAKE before drinking!!) 
Urine Sample Received 
Date 
Void# 
Bone Scan Done 
Milk Given 
INITIAL: Date 
Time 
FINAL: Date 
Date 
Amount 
Kind 
Time 
How/Where:..:: ___ _ 
Follow-Up/Final Data Gathering Visit Scheduled? 
Interviewer Initials: 
Blood Sample Obtained 
Date 
Lumbar 
Forearm 
Lumbar 
Forearm 
Date 
Amount 
Kind 
Time 
How/Where:..:  ___ _ 
YIN Date Scheduled For: 
% 
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DATA SHEET FOR CHILD WITHOUT CF 
CF Bone Mineralization Study Data Sheet for NON-CF/CONTROLS 
Date 
Name 
Group 
ID# 
Birthdate 
Sex 
Control# 
Anthropometry 
Height 
Weight 
BMI 
MAC 
AMC 
Arm Area 
AMA 
Triceps 
Subscapular 
Chest Circumf. 
Consent Form 
INITIAL 
Date: ___ _ 
_ Explained/Qstns Answered 
Signed? Y I N Date: 
Case-Match# __ _ 
Sibling/Relative 
FINAL 
Date: ___ _ 
Starter Packet Given & Explained 
_ 3-Day Diet Record Date 3-Day Record Returned: 
Medical History 
Previous Disease or Surgery: 
Current Disease/Health Problems: 
Previous Fractures(#, when, where): 
Medications: 
Vitamin/Supplement Use: 
Dairy or Other Food Intolerances: 
Usual Level of Activity: (Circle One) 
0 = no activity (ie stay in bed/watch tv all day) 
1 =light (less than other children of same age) 
2 = moderate (normal activity @ school/home but no extra exercise ) 
3 = high (normal activity + 20 min active play/exercise) 
4 = strenuous exercise for 20 min - 1 hr (ie basketball, soccer, dance) 
5 = strenuous, sustained exercise for 1 hr or longer 
Dad's Ht 
Mom's Ht 
(ie long distance running, endurance swimming, weight lifting) 
Bone Scan Done 
INITIAL: Date 
Time 
FINAL: Date 
Time 
Follow-Up/Final Data Gathering Visit Scheduled? 
Lumbar 
Forearm 
Lumbar 
Forearm 
Y/N Date Scheduled For: 
98 
99 
APPENDIX I 
3-DA Y DIET RECORD FORM 
CF BONE DENSITY STUDY 
FOOD AND BEVERAGE DIARY 
INSTRUCTIONS : 
1. Write down EVERYTHING you eat and drink for at least 3 days (before you start 
drinking the boxed milks). Don't forget water, soda, or "little nibbles ." 
2. Record information immediately after eating, drinking, or exercising. 
3. Include details about each food or beverage including the portion size, how the food 
was prepared, and any sauces or dressings on the food. 
4. Measure your food portions before you eat. If measuring is not possible, estimate the 
serving size. 
5. After you have recorded everything you eat and drink for 3 days on these sheets, 
please mail them back to Primary Children's Hospital in one of the stamped 
envelopes provided for you. 
EXAMPLE OF FOOD/BEVERAGE DIARY· 
TIME FOOD/BEVERAGE AMOUNT 
12:00 SANDWICH 
-WHITE BREAD 2 SLICES 
-PEANUT BUTTER, SMOOTH 3 TABLESPOONS 
-STRAWBERRY JAM 2 TABLESPOONS 
DIET ROOT BEER 120UNCECAN 
POT A TO CHIPS 15 CHIPS 
CELERY STICKS 5 SMALL 
CARROT STICKS 10 SMALL 
RANCH DRESSING 2 T ABELSPOONS 
Please complete the following information: 
NAME ____________________________ __ AGE __ _ 
ADDRESS ____________________________ _ 
PHONE ____________________________ __ 
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FOOD AND BEVERAGE DIARY 
Name Date 
TIME FOOD I BEVERAGE AMOUNT EATEN 
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APPENDIX J 
GUIDE TO PORTION SIZES FOR 3-DA Y DIET RECORD 
• This is a guide to help you figure out portion sizes for your 3-day diet record and daily calcium servings (on your daily log). 
SEVEN WAYS TO SIZE UP YOUR SERVINGS 
., 
Measure food portions so you know exactly how much food you're eating. 
When a food scale or measuring cups aren't handy, you can still estimate your portion. Remember: 
J 3 ounces of meat is about the size 
and thickness of a deck of playing 
cards or an audiotape cassette. 
2 A medium apple or 
peach is about the size 
of a tennis ball. 
3 I oz of cheese is about 
the size of 4 stacked dice. 
4 1h cup of ice cream 
is about the size of a 
racquetball or tennis ball . 
5 I cup of mashed potatoes or 
broccoli is about the size of 
your fist. 
6 I teaspoon of butter or 
peanut butter is about the 
size of the tip of your thumb. 
7 I ounce of nuts or 
small candies equals 
one handful. 
0 
MOST IMPORTANT 
Especially if you're cutting 
calories. remember to keep 
you r diet nutritious. 
R 2-4 servings from the 
U Milk Group for calcium 
03848 (I) 1996. Copyrigtll c 1996. 
NATIONAL OAlRY COUNCil.! Rosemont. ll 60018-5616. 
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i'i 2- 3 servings from the 
'9 Meat Group for iron 
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' 
3-5 servings from the 
Vegetable Group for vitamin A 
iiJiA 2-4 servings from the 
W Fruit Group for vitamin C 
0 6-11 servings from the Grain Group for fiber 
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DAILY LOG FORM 
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The Effect of Fortified Milk on Bone in Cystic Fibrosis Study Log 
Please fill this out every day. Refer to the scoring sheet on the back of the page. 
Name 
-----------------------
From Date· To Date· 
Monday Tuesday Wednesday Thursday Friday Saturday 
· Absorption 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 
Calcium 0 1 2 3 4 5 0 1 2 3 4 5 0 l 2 3 4 5 0 1 2 3 4 5 0123451012345 
r---· i I 
Enzymes 0 1 2 3 4 5 0 1 2 3 4 5 0 l 2 3 4 5 0 1 2 3 4 5 012345 ' 012345 
Vitamins Yes No Yes No Yes No Yes No Yes No Yes No 
- - - - - - - - -
Activity 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 
Comments 
L___ 
Sunday 
0 1 2 3 4 5 
0 1 2 3 4 5 
0 1 2 3 4 5 
Yes No 
- -
0 1 2 3 4 5 
-0 VI 
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SCORlNG GUIDE FOR DAILY LOG FORM 
Scoring for Study Log 
Absorption 
How many of the following symptoms of malabsorption did 
you have? Add 1 point for each: 
*More than 2 bowel movements in a day, 
* Large amount of stool or diarrhea, 
* Stool floats in toilet, 
* Visible grease/oil with stool in toilet , 
* Gas or bloating 
Calcium 
How many calcium- rich foods did you eat? 
*Add one point for each: 
8 ounce milk 
1 ounce cheese 
5 ounce yogurt 
*Add 1/2 point for each 
4 ounces pudding 
6 ounces cottage cheese 
3/4 cup broccoli 
Enzymes 
How many times did you miss taking enzymes or take enzymes 
after eating? Score according to the following : 
1 point - No enzymes at a meal 
1/2 point - No enzymes at snack 
1/2 point - Enzymes taken after a meal or snack instead of 
before eating. 
Vitamins 
Did you take your vitamin supplement today? 
Activity 
Rate your level of activity for the day: 
0 Stayed in bed or watched TV /played video games all day. 
1 Light activity in school or at home but less than other 
children of same age. 
2 Moderate activity - normal activity at school/home for age 
but no extra exercise. 
3 High activity - normal activity at school/home plus active 
play/exercise for at least 20 minutes. 
4 Strenuous exercise (elevated heart rate, breathing hard, 
sweating) sustained for at least 20 minutes but no 
longer than I hour. Examples, basketball or soccer 
game, dance class. Exercise is in addition to high levels 
of activity at home/school. 
5 Strenuous, sustained exercise (elevated heart rate, breathing 
hard, sweating) - high activity at home and school plus 
strenuous exercise for one hour or longer. Examples, 
long distance running, endurance swimming. 
Comments: 
How are things going? Good day, bad day? 
' 
...... 
s 
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APPENDIXM 
TIPS FOR IMPROVING DIGESTION 
* This is just meant to be a helpful reminder for you-- you don't need to fill it out for the study.© 
EASY IDEAS FOR IMPROVING ABSORPTION 
V Check the ones you are doing: 
___ Chew food well. 
___ Take enzymes with every calorie-containing food or beverage (especially milk) . 
___ Take vitamins with a meal or snack, after taking enzymes. 
___ Eat 5-6 times a day, but avoid "grazing" or constant nibbling (this includes milk or 
other calorie-containing beverages). 
___ Limit juices to less than 4 ounces per day. 
___ Take enzymes right before eating. 
_ __ For a big meal or a meal that lasts longer than 20-30 minutes, take an enzyme in the 
middle of the meal. 
Enzymes are fragile! 
___ Check expiration dates. Don't use expired enzymes. 
___ Keep enzymes _in a cool place. A void hot places like glove compartments in cars. 
Other suggestions: 
cyst icfi blcfpted.mat\easyidea. 798 
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APPENDIX N 
PATIENT HAND-OUT ON UHT MILK 
~ ii/l(l Gossner Foods UHT Milk 
1. WHAT IS U.H. T. SHELF STABLE MIL.K? 
Gassner's U.H.T. Shelf Stable Milk is a premium quality Grade A fluid milk. It has 
been specially processed and packaged so that no refrigeration is required until the 
package is opened. 
2. WHAT DOES U.H. T. STAND FOR? 
The letters U.H.T. stand for Ultra High Temperature. These letters are used to 
tell the consumer the milk or milk product has been subjected to a thermo process 
much higher than normal pasteurizing temperatures. 
' 
3. WHY DOESN'T U.H. T. SHEL.F STABLE MIL.K NEED REFRIGERATION? 
Gassner's U.H.T. Shelf Stable Milk is heated to 282 of and held for several 
seconds, then cooled to 70of in a continuous pressurized system. The milk is then 
packaged aseptically in a special Tetra Pak® container. The elevated temperatures 
are sufficient to destroy all pathogenic and spoilage bacteria, including spores. The 
special Tetra Pak® package is hermetically sealed to retain freshness . 
4 . WHAT IS ASEPTIC PACKAGING? 
A process by which a product is packaged free from bacteria. Our Tetra Pak® 
package is free from bacteria and hermetically sealed to keep out air and light. 
Bacteria, air and light are the basic ingredients that cause milk to sour, lose food 
value, and take on undesirable oxidized flavors . 
5. IS IT REAL. MIL.K? 
Yes, each package of Gossner foods U.H.T. Shelf Stable Milk carries the "Real" 
seal label, this gurantees that the milk is an authentic dairy product. Gossner Milk 
is Grade A liquid milk ready to use , just open the package and use , coolfor best 
results and refrigerate after opening. 
6. IS IT JUST AS NUTRITIOUS AS CONVENTIONAL. PASTEURIZED MIL.K? 
Yes, U.H.T. processing and foil lined aseptic packaging of Gassner's Shelf Stable 
Dairy Products ensures safety and long shelf life without significantly altering the 
product's nutritive value over the recommended use by date printed on the top of 
each hermetically sealed carton. 
7. ARE PRESERVATIVES USED OR ADDED TO THE MIL.K? 
No, preservatives are not added to Gossner Milk. 
8. HOW L.ONG DOES GOSSNER MIL.K L.AST? 
Gossner Milk can be stored on the shelf at room temperature for months before 
Ill 
being opened. It is recommended that it is used by the date stamped on the top of 
the carton. Once the package is opened it must remain refrigerated. 
9. IS AN ASEPTIC TETRA PAK@ PACKAGE SIMILAR TO A CAN? 
Yes, the package is a flexible can and should be treated like a can. If it is 
damaged, punctured or bloated it should be discarded and never used. 
10. WILL GOSSNER MILK SPOIL? 
Yes, if the package is damaged or if the package has been opened. Once the 
package is opened the milk is exposed to the air and will spoil just like pasteurized 
milk. Always refrigerate after opening for maximum shelf life. 
11. HOW SHOULD I STORE GOSSNER U.H. T. SHELF STABLE MILK? 
Store Gossner's Milk as you would store canned goods on the shelf at room 
temperatue 70°F or below. At higher temperatures (80oF to lOO oF) over a period 
I 
of weeks, the milk develops an off-color and taste; although, the milk remains 
sterile and is safe to use. 
12. FOR BEST RESULTS HOW SHOULD I USE GOSSNER SHELF STABLE MILK? 
For best taste results chill before drinking. Once the carton is opened, it must 
remain refrigerated as if it were pasteurized milk (use within approximately 5 
days). If straw has been inserted and used, refrigerate remaining milk and use 
within a day. Gossner Foods Milk Products are best if used by the code date 
printed on the top of each carton. 
13. WHERE CAN I BUY GOSSNER SHELF STABLE MILK? 
Availability of Gossner products varies with locations, however some stores that 
may carry Gossner UHT milk products are Macey's , Harmon's, Granato 's , Winegar's, 
Dan's Food Stores, and Ream's (selection may vary). 
SUGGESTIONS FOR USE OF U. H. T. MILK FOR CHILDREN WITH CF: 
(Remember ... it's important that children participating in the CF Bone Density Study 
consume the full 3 cartons of UHT milk each day!) 
* Add flavored syrups and powders for variety (i .e . strawberry or chocolate syrup, 
chocolate malt flavoring powder, etc.). 
* Pour over cold cereal or use to make hot cereal (i .e. oatmeal or creamed wheat). 
* Use to make nutrition shakes (i.e. Scandi-Shake, Carnation Instant Breakfast 
Powder, etc.) 
* Use to make pudding 
* Substitute for milk in any of your favorite recipes! 
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APPENDIXO 
FOLLOW-UP LETTER FOR PATIENTS ENROLLED IN STUDY 
1125/99 
Dear, 
Hello! Just wanted to ·send a quick note to check in on how you're doing with the CF Bone 
Density Study. I hope that everything's going well. If not, please don't hesitate to call with any 
questions or concerns you might have. I also wanted to let you know what we've received from 
you so far and what we still need. (If you've already mailed the following, please disregard--
our mail is a little slow sometimes!) Thank you for your participation. 
Sincerely, 
Joanna Kelley, RD 
(435) 753-3287 
We have received: 
Have not received: 
P.S. Just a reminder to schedule and attend your 3-month follow-up appointment for clinic so 
that we can get the final bone scan and anthropometric measurements completed. 
P.P.S . Please remember to shake the milk well before drinking it! 
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